UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of report (Date of earliest event reported): August 11, 2021
Rockley Photonics Holdings Limited
(Exact name of registrant as specified in its charter)
Cayman Islands | 001-40735 | Not Applicable | ||
(State or other jurisdiction of incorporation) |
(Commission File Number) |
(I.R.S. Employer Identification No.) |
3rd Floor, 1 Ashley Road Altrincham, Cheshire, United Kingdom |
WA14 2DT | |
(Address of principal executive offices) | (Zip Code) |
+44 (0) 1865 292017
(Registrants telephone number, including area code)
Not Applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
☐ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
☐ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
☐ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
Title of each class |
Trading Symbol(s) |
Name of each exchange on which registered |
||
Ordinary shares, nominal value $.000004026575398 per share | RKLY | The New York Stock Exchange | ||
Warrants, each warrant exercisable for one ordinary share at an exercise price of $11.50 | RKLYW | The New York Stock Exchange |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
INTRODUCTORY NOTE
On August 11, 2021, Rockley Photonics Holdings Limited, an exempted company incorporated in the Cayman Islands with limited liability (HoldCo, Rockley, or the Company), Rockley Photonics Limited, a company organized under the laws of England and Wales (Rockley UK), and SC Health Corporation, an exempted company incorporated in the Cayman Islands with limited liability (SC Health), consummated the previously announced business combination (the Business Combination) contemplated by the Business Combination Agreement and Plan of Merger, dated March 19, 2021 (the Business Combination Agreement), by and among HoldCo, Rockley UK, SC Health, and Rockley Mergersub Limited, an exempted company incorporated in the Cayman Islands with limited liability and a direct wholly owned subsidiary of HoldCo (Merger Sub).
Pursuant to the Business Combination Agreement, each of the following transactions occurred in the following order: (i) pursuant to a scheme of arrangement approved by the UK courts (the Scheme), at 10:10 a.m., Pacific time, on August 9, 2021 (1:10 p.m., Eastern time, on August 9, 2021), all of Rockley UKs ordinary shares, including shares issued immediately prior to the Scheme becoming effective as a result of the conversion of then-outstanding convertible loan notes and the exercise of warrants, were transferred by Rockley UK shareholders in exchange for an equivalent number of shares in HoldCo; (ii) the holders of options over shares in Rockley UK rolled over their options into new options over shares in HoldCo; (iii) warrants over shares in Rockley UK (other than one warrant instrument that by its terms was replicated at HoldCo) not exercised for shares in Rockley UK prior to the effectiveness of the Scheme described above were cancelled, such that immediately following the Scheme as described in (i) above, Rockley UK became a direct wholly-owned subsidiary of HoldCo; (iv) HoldCo completed a stock-split to prepare its share capital for Merger Subs merger into SC Health; (v) certain investors (including entities affiliated with the Sponsor) purchased an aggregate of $150,000,000 of ordinary shares in HoldCo pursuant to the PIPE Financing described below; (vi) at 1:01 p.m., Pacific time on August 11, 2021 (4:01 p.m., Eastern time, on August 11, 2021), Merger Sub was merged with and into SC Health, with SC Health surviving the merger and becoming a direct wholly-owned subsidiary of HoldCo; and (vii) the ordinary shares and warrants in SC Health were exchanged for ordinary shares and warrants in HoldCo.
A description of the Business Combination and the terms of the Business Combination Agreement are included in the Registration Statement on Form S-4 (File No. 333-255019) (the Registration Statement) filed by HoldCo in connection with the Business Combination and declared effective by the Securities and Exchange Commission (the SEC) on July 22, 2021in the section titled Proposal No. 1 BCA Proposal, including under the subsection thereof titled The Business Combination Agreement and Plan of Merger beginning on page 104 of the Registration Statement, which is incorporated herein by reference. The foregoing description does not purport to be complete and is qualified in its entirety by the full text of the Business Combination Agreement, a copy of which was filed as Exhibit 2.1 to the Registration Statement and incorporated by reference as Exhibit 2.1 to this Current Report on Form 8-K (the Current Report), which is incorporated herein by reference.
In connection with the Business Combination, on March 19, 2021, HoldCo and SC Health entered into the subscription agreements (the Subscription Agreements), by and among each subscriber (including entities affiliated with the Sponsor and collectively, the Subscribers), SC Health, and HoldCo, pursuant to which the Subscribers agreed to purchase an aggregate of 15,000,000 ordinary shares of HoldCo (the PIPE Shares), for a purchase price of $10.00 per share and an aggregate purchase price of $150 million. Subscribers affiliated with the Sponsor purchased $50 million of the PIPE Shares. Pursuant to the Subscription Agreements, HoldCo gave certain registration rights to the Subscribers with respect to the PIPE Shares. The sale of PIPE Shares was consummated concurrently with the closing of the Business Combination (the Closing).
A description of the Subscription Agreements is included in the Registration Statement in the sections titled Proposal No. 1 BCA Proposal Related Agreements PIPE Subscription Agreements beginning on page 131 of the Registration Statement and Certain Relationships and Related Party Transactions Subscription Agreements beginning on page 275 of the Registration Statement, and under Item 3.02 of this Current Report, which are incorporated herein by reference. These descriptions do not purport to be complete and are qualified in their entirety by reference to the text of the forms of Subscription Agreements filed as Exhibits 10.4 and 10.5 to the Registration Statement and incorporated by reference as Exhibits 10.1 and 10.2 hereto, which are incorporated herein by reference.
At 1:00 p.m. Pacific time (4:00 p.m. Eastern time) on August 11, 2021, SC Healths units, the SC Health ordinary shares and the SC Health warrants ceased trading on The New York Stock Exchange (the NYSE), and the HoldCo ordinary shares and warrants began trading on the NYSE under the symbols RKLY and RKLYW, respectively.
Certain terms used in this Current Report not defined herein have the same meaning as set forth in the Registration Statement. In addition, references to the Company and Rockley herein may also refer to the combined entity after the Closing, as the context requires.
2
Item 1.01. Entry into a Material Definitive Agreement
Warrant Agreement
In connection with the Closing, on August 11, 2021, SC Health, HoldCo, and Computershare Trust Company, N.A (Computershare), as warrant agent, entered into an assignment, assumption, and amendment agreement (the HoldCo Warrant Agreement), which replaced and superseded the warrant agreement, dated July 11, 2019, between SC Health, the Sponsor, and American Stock Transfer & Trust Company (the SC Health Warrant Agreement). The SC Health Agreement was terminated on August 11, 2021 in connection with the Closing. Pursuant to the HoldCo Warrant Agreement, as of the Merger Effective Time, (a) each SC Health warrant that was outstanding immediately prior to the Merger Effective Time no longer represented a right to acquire one SC Health ordinary share and instead represented the right to acquire one HoldCo ordinary share under the same terms as set forth in the SC Health Warrant Agreement, and (b) SC Health assigned to HoldCo all of SC Healths right, title, and interest in and to the SC Health Warrant Agreement and HoldCo assumed, and agreed to pay, perform, satisfy, and discharge in full, all of SC Healths liabilities and obligations under the SC Health Warrant Agreement arising from and after the Merger Effective Time.
The foregoing descriptions of the HoldCo Warrant Agreement and the SC Health Warrant Agreement are qualified in their entirety by reference to the full text of the HoldCo Warrant Agreement filed as Exhibit 4.2 and the SC Health Warrant Agreement filed as Exhibit 4.1 to the Registration Statement and incorporated by reference as Exhibits 4.2 and 4.1, respectively, hereto, which are incorporated herein by reference.
Registration Rights and Lock-Up Agreement
In connection with, and as a condition to, the Closing, the Sponsor and certain shareholders and optionholders of HoldCo (formerly shareholders and optionholders of Rockley UK) (the Target Holders) entered into a Registration Rights and Lock-Up Agreement (the Registration Rights Agreement), pursuant to which, among other things, HoldCo agreed to undertake certain shelf registration obligations in accordance with the U.S. Securities Act of 1933, as amended (the Securities Act) and certain subsequent related transactions and obligations, including, among other things, undertaking certain registration obligations, and the preparation and filing of required documents. The Sponsor and Target Holders agreed to be bound by certain transfer restrictions with respect to the shares they receive in HoldCo. The terms of the Registration Rights and Lock-Up Agreement are described in the Registration Statement in the sections titled Proposal No. 1 BCA Proposal Related Agreements Registration Rights and Lock-Up Agreement beginning on page 130 of the Registration Statement and Certain Relationships and Related Party Transactions Registration Rights and Lock-Up Agreements beginning on page 276 of the Registration Statement, which are incorporated herein by reference.
The foregoing description of the Registration Rights Agreement is subject to and qualified in its entirety by reference to the full text of the form of the Registration Rights Agreement, a copy of which was filed as Exhibit 10.6 to the Registration Statement and is incorporated by reference as Exhibit 10.3 to this Current Report, which is incorporated herein by reference.
Lock-Up Agreements
In connection with the Business Combination, on August 11, 2021, HoldCo and certain shareholders and executives of Rockley UK entered into a Lock-Up Agreement (each, a Lock-Up Agreement). The terms of the Lock-Up Agreements provide for the ordinary shares held by such shareholders to be locked-up for a period of 180 days after the Closing Date, subject to certain exceptions.
The foregoing description of the Lock-Up Agreements is qualified in its entirety by the full text of the Lock-Up Agreements, a form of which is attached hereto as Exhibit 4.5, and which is incorporated herein by reference.
2021 Stock Incentive Plan
Prior to the Closing, the Company adopted the Rockley Photonics Holdings Limited 2021 Stock Incentive Plan of Rockley (the 2021 Plan) that was considered and approved by SC Health shareholders at the extraordinary general meeting of the SC Health shareholders held on August 6, 2021, and approved by HoldCo and Rockley UK, to be effective as of and contingent on the Closing. The purpose of the 2021 Plan is to enhance HoldCos ability to attract, retain, incentivize, reward, and motivate persons who make (or are expected to make) important contributions by providing these individuals with equity ownership opportunities and/or equity-linked compensatory opportunities.
3
HoldCos employees, consultants and directors, and employees, consultants and directors of its subsidiaries will be eligible to receive awards under the 2021 Plan. The 2021 Plan will be administered by the compensation committee of the HoldCo board of directors or by the HoldCo board of directors acting as the compensation committee, each of which may delegate its duties and responsibilities to committees of HoldCo directors and/or officers (referred to collectively as the plan administrator below), subject to certain limitations that may be imposed under Section 16 of the Securities Exchange Act of 1934, as amended (the Exchange Act), and/or stock exchange rules, as applicable. Subject to the limitations set forth in the 2021 Plan, the compensation committee will have the authority to determine, among other things, to whom awards will be granted, the number of shares subject to awards, the term during which an option or stock appreciation right may be exercised and the rate at which the awards may vest or be earned, including any performance criteria to which they may be subject. The compensation committee also will have the authority to determine the consideration and methodology of payment for awards. To the extent permitted by applicable law, the board of directors or compensation committee may also authorize one or more officers of HoldCo to designate employees, other than officers under Section 16 of the Exchange Act, to receive awards and/or to determine the number of such awards to be received by such persons subject to a maximum total number of awards.
The aggregate number HoldCo ordinary shares on an as-converted basis that may be issued pursuant to stock awards after the Closing under the 2021 Plan will not exceed the sum of (x) 7,631,196 shares, plus (y) the sum of the number of shares subject to outstanding awards under the Rockley Photonic Limited 2013 Equity Incentive Plan, as amended (the 2013 Plan), following the Effective Date that (i) are subsequently forfeited or terminated for any reason before being exercised or settled, (ii) are not issued because such stock award or any portion thereof is settled in cash, (iii) are subject to vesting restrictions and are subsequently forfeited, (iv) are withheld or reacquired to satisfy the exercise, strike or purchase price, or (v) are withheld or reacquired to satisfy a tax withholding obligation, plus (z) the number of shares reserved on an as-converted basis which, but for their cancellation immediately prior to the Effective Date, were at such time under the 2013 Plan but not issued or subject to outstanding grants under the 2013 Plan. In addition, the share reserve will be subject to an annual increase on the first day of each fiscal year, for a period of not more than 10 years, beginning on January 1, 2022 and ending on (and including) January 1, 2031, in an amount equal to the lesser of (i) four percent (4%) of the outstanding shares on the last day of the immediately preceding fiscal year or (ii) such lesser amount (including zero) that the compensation committee determines for purposes of the annual increase for that fiscal year.
If restricted shares or shares issued upon the exercise of options are forfeited, then such shares shall again become available for awards under the 2021 Plan. If stock units, options, or stock appreciation rights are forfeited or terminate for any reason before being exercised or settled, or an award is settled in cash without the delivery of shares to the holder, then the corresponding shares will again become available for awards under the 2021 Plan. Any shares withheld to satisfy the exercise price or tax withholding obligation pursuant to any award of options or stock appreciation rights shall again become available for awards under the 2021 Plan. If stock units or stock appreciation rights are settled, then only the number of shares (if any) actually issued in settlement of such stock units or stock appreciation rights shall reduce the number of shares available under the 2021 Plan, and the balance (including any shares withheld to cover taxes) shall again become available for awards under the 2021 Plan.
Awards granted under the 2021 Plan upon the assumption of, or in substitution for, outstanding equity awards previously granted by an entity in connection with a corporate transaction, such as a merger, combination, consolidation or acquisition of property or shares will not reduce the number of shares authorized for grant under the 2021 Plan. The sum of (i) the grant date fair value for financial reporting purposes of any awards granted during any calendar year under the 2021 Plan to an outside director as compensation for services as an outside director and (ii) any cash fees paid by HoldCo to such outside director during such calendar year for service on HoldCos board of directors, may not exceed $750,000 (other than in the calendar year in which the outside director commences service). In addition, initial awards granted under the 2021 Plan to outside directors who are members of the board on the Effective Date or who first join the board in the calendar year of the Effective Date will not be taken into account for purposes of this limitation.
The 2021 Plan provides for the grant of stock options, including incentive stock options (ISOs) and non-qualified stock options (NSOs), restricted share awards, stock unit awards, stock appreciation rights, other stock-based awards, and cash-based awards, and performance-based stock awards, (collectively, stock awards). ISOs may be granted only to HoldCos employees, including officers, and the employees of HoldCos parent or subsidiaries. All other stock awards may be granted to HoldCos employees, officers, HoldCos non-employee directors, and consultants and the employees and consultants of HoldCos parent, subsidiaries, and affiliates. Certain awards under the 2021 Plan may constitute or provide for a deferral of compensation, subject to Section 409A of the Internal Revenue Code of 1986, as amended (the Code), which may impose additional requirements on the terms and conditions of such awards. All awards under the 2021 Plan will be set forth in award agreements, which will detail all terms and conditions of the awards, including any applicable vesting and payment terms and post-termination exercise limitations. Awards, other than cash awards, generally will be settled in HoldCo ordinary shares, but the plan administrator may provide for cash settlement of any award.
4
No award may be granted pursuant to the 2021 Plan after the tenth anniversary of March 31, 2021, the date on which the sole director of HoldCo adopted the 2021 Plan prior to the Closing.
Additional information regarding the terms of the 2021 Plan is set forth in the Registration Statement in the section titled Proposal No. 3 Incentive Plan Proposal beginning on page 152 of the Registration Statement, which is incorporated herein by reference. That summary and the foregoing description of the 2021 Plan do not purport to be complete and are qualified in their entirety by reference to the text of the 2021 Plan, the form of which was filed as Annex H to the Registration Statement and which is filed as Exhibit 10.5 hereto, which is incorporated herein by reference.
2021 Employee Stock Purchase Plan
Prior to the Closing, the Company adopted the Rockley Photonics Holdings Limited 2021 Employee Stock Purchase Plan (the ESPP), effective as of and contingent on the Closing. Under the ESPP, HoldCo will be authorized to provide eligible employees with an opportunity to request payroll deductions to purchase a number of HoldCo ordinary shares at a discount and in an amount determined in accordance with the ESPPs terms.
The purpose of the ESPP is to provide a broad-based employee benefit to attract the services of new employees, to retain the services of existing employees, and to provide incentives for such individuals to exert maximum efforts toward our success by purchasing HoldCo ordinary shares from HoldCo on favorable terms and to pay for such purchases through payroll deductions. HoldCo believes by providing eligible employees with an opportunity to increase their proprietary interest in the success of HoldCo, the ESPP will motivate recipients to offer their maximum effort to HoldCo and help focus them on the creation of long-term value consistent with the interests of the HoldCo shareholders.
The ESPP is intended to qualify as an employee stock purchase plan under Code Section 423, except as explained below with respect to non-U.S. employees. During regularly scheduled offerings under the ESPP, participants will be able to request payroll deductions and then expend the accumulated deduction to purchase a number of HoldCo ordinary shares at a discount and in an amount determined in accordance with the ESPPs terms.
The ESPP will have 1,526,239 authorized but unissued or reacquired HoldCo ordinary shares reserved for issuance under the ESPP after the Closing of the Business Combination, plus an additional number of shares to be reserved annually on the first day of each fiscal year for a period of not more than ten years, beginning on January 1, 2022, in an amount equal to the least of (i) one percent (1%) of the outstanding HoldCo ordinary shares on such date (ii) 7,631,196 shares, or (iii) a lesser amount (including zero) that the compensation committee of the HoldCo board of directors determines for purposes of the annual increase for that fiscal year.
The ESPP will be administered by the compensation committee, or by HoldCos board of directors acting as the compensation committee. The compensation committee has the authority to construe, interpret and apply the terms of the ESPP, to determine eligibility, to establish such limitations and procedures as it determines are consistent with the ESPP and to adjudicate any disputed claims under the ESPP.
Each employee of HoldCo and any of its participating subsidiaries who is employed by HoldCo (or its participating subsidiaries) on the day preceding the start of any offering period, will be eligible to participate in the ESPP. The ESPP requires that any such employee customarily work more than twenty (20) hours per week and more than five (5) months per calendar year with HoldCo (or its participating subsidiaries) in order to be eligible to participate in the ESPP. The ESPP will permit an eligible employee to purchase HoldCo ordinary shares through payroll deductions, which may not be less than one percent (1%) nor more than fifteen percent (15%) of the employees compensation, or such lower limit as may be determined by the Compensation Committee from time to time. However, no employee is eligible to participate in the ESPP if, immediately after electing to participate, the employee would own stock (including stock such employee may purchase under this plan or other outstanding options) representing five percent (5%) or more of the total combined voting power or value of all classes of HoldCos stock. No employee will be able to purchase more than five thousand (5,000) shares, or such number of shares as may be determined by the Compensation Committee with respect to a single offering period, or purchase period, if applicable. In addition, no employee is permitted to accrue, under the ESPP and all similar purchase plans of HoldCo or its subsidiaries, a right to purchase stock of the HoldCo having a value in excess of $25,000 of the fair market value of such stock (determined at the time the right is granted) for each calendar year. Employees will be able to withdraw their accumulated payroll deductions prior to the end of the offering period in accordance with the terms of the offering. Participation in the ESPP will end automatically on termination of employment.
5
The ESPP will be implemented through a series of offerings of purchase rights to eligible employees. Under the ESPP, the compensation committee may specify offerings with a duration of not more than 27 months and may specify shorter purchase periods within each offering. During each purchase period, payroll deductions will accumulate, without interest. On the last day of the purchase period, accumulated payroll deductions will be used to purchase HoldCo ordinary shares for employees participating in the offering.
The purchase price will be specified pursuant to the offering, but cannot, under the terms of the ESPP, be less than eighty-five percent (85%) of the fair market value per HoldCo ordinary share on either the offering date or on the purchase date, whichever is less. The fair market value of HoldCo ordinary shares for this purpose will generally be the closing price on the NYSE (or such other exchange as the HoldCo ordinary shares may be traded at the relevant time) for the date in question, or if such date is not a trading day, for the last trading day before the date in question.
The compensation committee may specify that, if the fair market value of HoldCo ordinary shares on any purchase date within a particular offering period is less than or equal to the fair market value on the start date of that offering period, then the offering period will automatically terminate and the employee in that offering period will automatically be transferred and enrolled in a new offering period which will begin on the next day following such purchase date.
To provide HoldCo with greater flexibility in structuring HoldCos equity compensation programs for HoldCos non-U.S. employees, the ESPP also permits HoldCo to grant employees of HoldCos non-U.S. subsidiary entities rights to purchase HoldCo ordinary shares pursuant to other offering rules or sub-plans adopted by the compensation committee in order to achieve tax, securities law, or other compliance objectives. The international sub-plans or offerings are subject to the ESPP terms limiting the overall shares available for issuance, the maximum payroll deduction rate, maximum purchase price discount and maximum offering period length.
Additional information regarding the ESPP is set forth in the Registration Statement in the section titled Proposal No. 4 ESPP Proposal beginning on page 159 of the Registration Statement, which is incorporated herein by reference. That summary and the foregoing description of the 2021 Plan do not purport to be complete and are qualified in their entirety by reference to the text of the 2021 Plan, the form of which was filed as Annex I to the Registration Statement and which is filed as Exhibit 10.7 hereto, which is incorporated herein by reference.
Non-Employee Director Compensation Policy
The Companys policy is to reimburse directors for reasonable and necessary out-of-pocket expenses incurred in connection with attending board of directors and committee meetings or performing other services in their capacities as directors. Effective upon the Closing, HoldCos board of directors approved a non-employee director compensation policy (the Director Compensation Program), consisting of annual retainer fees and long-term equity awards for HoldCos non-employee directors.
Under the Director Compensation Program and in connection with the Closing, HoldCo will grant RSUs to each non-employee director (each an Initial RSU Award) under the 2021 Plan covering HoldCo ordinary shares with an aggregate fair market value of $220,000 determined at the date of grant or, for non-employee directors who joined the HoldCo board prior to the date, such RSUs may be issued under applicable U.S. securities laws, the later of the date such non-employee director joined the HoldCo board of directors or the Closing. Each Initial RSU Award vests as to 1/3 of the total number of shares subject to the award on the earlier of the first anniversary of the date of grant or the next annual meeting of HoldCos shareholders, and in each of the next two calendar years following the year of the initial vesting date, 1/3 of the total number of shares shall vest on the earlier of the one-year anniversary of the prior annual meeting of shareholders or the current year annual meeting of shareholders. However, for directors who join the board before the date such RSUs may be issued under applicable U.S. securities laws, for purposes of determining the applicable vesting schedule of such Initial RSU Award, the date on which such director joins the board (or if later, the Closing) shall be treated as the date of grant of the award. Each Initial RSU Award shall become 100% vested if a change in control as defined in the 2021 Plan occurs during such directors service.
In addition, under the Director Compensation Program, following the conclusion of each regular annual meeting of HoldCos shareholders, commencing with the 2022 annual meeting, each non-employee director who will continue serving as a member of HoldCos board of directors thereafter shall receive a grant of RSUs (each an Annual RSU Award) under the 2021 Plan covering HoldCo ordinary shares with an aggregate grant date fair market value of $162,000. In addition, if a non-employee director is elected to the HoldCo board of directors other than at an annual meeting of shareholders after the 2022 annual meeting of shareholders and the non-employee director shall receive an Annual RSU Award upon election to HoldCos board of directors that is prorated based upon the number of calendar days remaining before (1) the next annual meeting of shareholders, if scheduled, or (2) the date of the first anniversary of the last annual meeting of shareholders, if the next annual meeting is not yet scheduled.
Each Annual RSU Award shall become fully vested, subject to the applicable non-employee directors continued service as a director, on the earliest of the one-year anniversary of the date of grant, the next annual meeting of shareholders following the date of grant or the consummation of a change in control as defined in the 2021 plan.
The Director Compensation Program also consists of the following cash components:
|
Annual Retainer for all non-employee directors: $45,000 |
6
|
Lead Director Retainer: $23,000 |
|
Annual Committee Chair Retainer: |
|
Audit: $20,000 |
|
Nominating and Corporate Governance $10,000 |
|
Compensation: $15,000 |
|
Annual Committee Member (Non-Chair) Retainer: |
|
Audit: $10,000 |
|
Nominating and Corporate Governance: $5,000 |
|
Compensation: $7,500 |
The annual cash retainer will be paid in quarterly installments in arrears following the end of each quarter in which the service occurred, pro-rated for any partial months of service.
Additional information regarding the terms of the Non-Employee Director Compensation Policy is set forth in the Registration Statement in the section titled Director Compensation beginning on page 269 of the Registration Statement, which is incorporated herein by reference. That summary and the foregoing description of the Director Compensation Policy do not purport to be complete and are qualified in their entirety by reference to the text of the Non-Employee Director Compensation Policy, which is filed as Exhibit 10.30 hereto and is incorporated herein by reference.
The disclosure contained in Item 2.03 of this Current Report is incorporated herein by reference.
Indemnification Agreement
Upon the Closing, effective August 11, 2021, HoldCo entered into indemnification agreements with its directors and executive officers. These agreements, among other things, require HoldCo to indemnify HoldCos directors and executive officers for certain expenses, including attorneys fees, judgments, fines, and settlement amounts incurred by a director or executive officer in any action or proceeding arising out of their services as one of HoldCos directors or executive officers or as a director or executive officer of any other company or enterprise to which the person provides services at HoldCos request. The disclosure contained in the Registration Statement in the sections titled Management of HoldCo Following the Business Combination on pages 250-251 of the Registration Statement, and Certain Relationships and Related Party Transactions Indemnification Agreements beginning on page 278 of the Registration Statement is incorporated herein by reference.
The foregoing description of the indemnification agreements does not purport to be complete and is qualified in its entirety by reference to the text of the form of indemnification agreement, which was filed as Exhibit 10.7 to the Registration Statement and is incorporated by reference as Exhibit 10.4 hereto, which is incorporated herein by reference.
Amended Facility Agreement
The disclosure set forth under Item 2.03 of this Current Report on Form 8-K is incorporated herein by reference.
Item 2.01. Completion of Acquisition or Disposition of Assets
The disclosure set forth in the Introductory Note above is incorporated by reference into this Item 2.01.
On August 6, 2021, SC Health held an extraordinary general meeting of the SC Health shareholders at which the SC Health shareholders considered and adopted, among other matters, the Business Combination Agreement. On August 11, 2021, the parties to the Business Combination Agreement consummated the Business Combination.
In connection with such extraordinary general meeting and approval of the Business Combination, holders of 7,517,365 SC Health Class A ordinary shares (the Public Shares) exercised their right to redeem those shares for cash at a price of approximately $10.12 per share, for an aggregate amount of approximately $76 million. The redemption price for holders of Public Shares electing redemption was paid out of SC Healths trust account, which had a balance immediately prior to the Closing of approximately $93.8 million. In addition, the holders of SC Health public warrants had the right to require the Sponsor to repurchase such warrants at a price of $1.00 per share, which repurchase amounts were to be paid out of a separate escrow account funded by the Sponsor. No holders of SC Health public warrants exercised such repurchase rights in connection with the Business Combination.
7
Prior to the Merger Effective Time, HoldCo issued the PIPE Shares to the Subscribers, including 5,000,000 shares issued to Subscribers affiliated with the Sponsor, at a purchase price of $10.00 per share and an aggregate purchase price of $150 million.
In connection with the Closing, the existing holders of securities in Rockley UK exchanged their securities for HoldCo securities, HoldCo effected a stock split such that the number of shares outstanding in HoldCo equaled approximately $1,148,114,113 divided by $10.00 (subject to certain adjustments), the Subscribers purchased 15,000,000 HoldCo ordinary shares for proceeds of $150,000,000, as further described under the caption PIPE Financing in Item 3.02 of this Current Report, which disclosure is incorporated herein by reference, and the SC Health ordinary shares and warrants were exchanged for HoldCo ordinary shares and warrants on a 1:1 basis.
Immediately after giving effect to the Business Combination (including as a result of the redemptions and repurchases described above and the PIPE), there were 126,256,257 HoldCo ordinary shares outstanding (the Outstanding Shares) (including 103,916,607 shares issued to former Rockley UK equity holders, 10,000,000 shares issued in the PIPE (excluding shares issued to Sponsor-affiliated Subscribers in the PIPE), 5,000,000 shares issued to Sponsor-affiliated Subscribers in the PIPE, and 7,319,650 HoldCo ordinary shares issued to former SC Health shareholders, of which 5,562,500 HoldCo ordinary shares were issued to the Sponsor (excluding shares issued to Sponsor-affiliated Subscribers in the PIPE), and excluding an aggregate of 16,565,077 shares issuable pursuant to outstanding equity awards (subject to vesting), 6,400,739 shares issuable pursuant to the conversion of outstanding convertible loan notes, and 14,204,266 shares issuable upon the exercise of outstanding warrants.
In connection with the Closing, on August 11, 2021, SC Healths units, SC Health ordinary shares and SC Health warrants ceased trading on the NYSE, and HoldCo ordinary shares and HoldCo warrants began trading on the NYSE under the symbols RKLY and RKLYW, respectively. As of the Closing, the former securityholders of Rockley UK beneficially owned approximately 82.3% of the Outstanding Shares, the former shareholders of SC Health (including the Sponsor) beneficially owned approximately 9.8% of the Outstanding Shares (including the PIPE shares purchased by entities affiliated with the Sponsor), and the investors in the PIPE (excluding entities affiliated with the Sponsor) beneficially owned approximately 7.9% of the Outstanding Shares. Holders affiliated with the Sponsor beneficially owned approximately 8.4% of the Outstanding Shares upon the Closing. The foregoing does not give effect to the 1,250,000 shares transferred by Sponsor-related entities to an unrelated third party to facilitate the financing of the Sponsor-affiliated Subscribers purchase in the PIPE Financing
FORM 10 INFORMATION
Immediately before the Closing, each of HoldCo and SC Health was a shell company, other than a business combination related shell company, as those terms are defined in Rule 12b-2 under the Exchange Act. Pursuant to Item 2.01(f) of Form 8-K, HoldCo is providing the information below that would be included in a Form 10 if HoldCo were to file a Form 10.
Forward-Looking Statements
Statements in this Current Report or in the disclosures or documents incorporated herein by reference that are not historical facts constitute forward-looking statements. These forward-looking statements include statements regarding Rockleys future expectations, beliefs, plans, prospects, objectives, and assumptions regarding future events or performance, as well as Rockleys strategies, future operations, financial position, and estimated future financial results and anticipated costs. The words anticipate, believe, continue, could, enable, estimate, eventual, expect, future, intend, may, might, opportunity, outlook, plan, possible, position, potential, predict, project, revolutionize, seem, should, trend, will, would, and other terms that predict or indicate future events, trends, or expectations, and similar expressions or the negative of such expressions may identify forward-looking statements, but the absence of these words or terms does not mean that a statement is not forward-looking.
The forward-looking statements contained in this Form 8-K, and the disclosures and documents incorporated herein by reference, are based on information available as of the date of this Current Report, and current expectations, forecasts, and assumptions, (whether or not identified herein), and involve a number of risks and uncertainties. Accordingly, forward-looking statements in this Current Report and in any disclosure or document incorporated herein by reference should not be relied upon as representing Rockleys views as of any subsequent date, and Rockley does not undertake any obligation to update forward-looking statements to reflect events or circumstances after the date they were made, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws.
8
Forward-looking statements are subject to several risks and uncertainties (many of which are beyond Rockleys control) or other assumptions that may cause actual results or performance to differ materially from those expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to, the following:
|
the Companys ability to achieve commercial production of its products and technology, including in a timely and cost-effective manner; |
|
the Companys ability to achieve customer design wins, convert memoranda of understanding and development contracts into production contracts, and achieve customer acceptance of its products and technology; |
|
risks related to purchase orders, including the lack of long-term purchase commitments, the cancellation, reduction, delay, or other changes in customer purchase orders, and if and to the extent customers seek to enter into licensing arrangements in lieu of purchases; |
|
the Companys history of losses and need for additional capital and its ability to access additional financing to support its operations and execute on its business plan, as well as the risks associated with any future financings; |
|
legal and regulatory risks, including those related to its products and technology and any threatened or actual litigation; |
|
risks associated with its fabless manufacturing model and dependency on third-party suppliers; |
|
the Companys reliance on a few significant customers for a majority of its revenue and its ability to expand and diversify its customer base; |
|
the Companys financial performance; |
|
the impacts of COVID-19 on the Company, its customers and suppliers, its target markets, and the economy; |
|
the Companys ability to successfully manage growth and its operations as a public company; |
|
fluctuations in the Companys stock price and the Companys ability to maintain the listing of its ordinary shares on the NYSE; |
|
the Companys ability to anticipate and respond to industry trends and customer requirements; |
|
changes in the Companys current and future target markets; |
|
intellectual property risks; |
|
the Companys ability to compete successfully |
|
market opportunity and market demand for, and acceptance of, the Companys products and technology, as well as the customer products into which the Companys products and technology are incorporated |
|
risks related to international operations |
|
risks related to cybersecurity, privacy, and infrastructure |
|
risks related to financial and accounting matters; |
|
general economic, financial, legal, political, and business conditions and changes in domestic and foreign markets; |
|
the Companys ability to realize the anticipated benefits of the Business Combination and costs associated with the Business Combination; |
|
changes adversely affecting the businesses or markets in which the Company is engaged, and |
9
|
other factors described under the heading Risk Factors in the Registration Statement and in other documents the Company files with the Securities and Exchange Commission in the future. |
Business
The business of HoldCo, Rockley UK, and SC Health prior to the Business Combination are described in the Registration Statement in the sections titled Information About SC Health beginning page 191 of the Registration Statement, and Information About Rockley beginning on page 199 of the Registration Statement, which are incorporated herein by reference.
Risk Factors
The risks associated with Rockleys business as set forth in the Registration Statement in the section titled Risk Factors beginning on page 48 of the Registration Statement, and in HoldCos quarterly report on Form 10-Q for the quarter ended June 30, 2021 (the HoldCo 10-Q) in the section titled Item 1A. Risk Factors are incorporated herein by reference.
Financial Information
Audited and Unaudited Financial Information
The audited consolidated financial statements of Rockley UK as of and for the year ended December 31, 2020 are incorporated by reference from the audited consolidated financial statements on pages F-2 through F-37 of the Registration Statement.
The unaudited condensed consolidated financial statements as of and for the three months ended March 31, 2021 of Rockley UK are incorporated by reference from the unaudited condensed consolidated financial statements on pages F-38 through F-64 of the Registration Statement, which is incorporated by reference herein. The unaudited condensed consolidated financial statements as of and for the six months ended June 30, 2021 of HoldCo are incorporated by reference from the unaudited condensed consolidated financial statements in the HoldCo 10-Q. Such unaudited condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles and pursuant to the regulations of the SEC. The unaudited condensed consolidated financial information reflects, in the opinion of management, all adjustments, consisting of normal recurring adjustments, considered necessary for a fair statement of the Companys financial position, results of operations and cash flows for the periods indicated. The results reported for the interim period presented are not necessarily indicative of results that may be expected for the full year.
These unaudited condensed consolidated financial statements should be read in conjunction with the historical audited consolidated financial statements of Rockley UK as of and for the year ended December 31, 2020 and the related notes included in the Registration Statement, the section titled Rockleys Managements Discussion and Analysis of Financial Condition and Results of Operations beginning on page 222 of the Registration Statement and the section entitled Managements Discussion and Analysis of Financial Condition and Results of Operations included the HoldCo 10-Q, which are incorporated herein by reference.
Unaudited Pro Forma Condensed Consolidated Combined Financial Information
The unaudited pro forma condensed combined financial information of the Company as of and for the year ended December 31, 2020 is included in the Registration Statement in the section titled Unaudited Pro Forma Condensed Combined Financial Information beginning on page 179 of the Registration Statement, which is incorporated herein by reference.
The unaudited pro forma condensed combined financial information of the Company as of and for the three months ended March 31, 2021 is included in the Registration Statement in the section titled Unaudited Pro Forma Condensed Combined Financial Information beginning on page 179 of the Registration Statement, which is incorporated herein by reference.
The unaudited pro forma condensed combined financial information of the Company as of and for the six months ended June 30, 2021 is included as Exhibit 99.1 to this Current Report, which is incorporated herein by reference.
The disclosure set forth in Item 9.01 of this Current Report concerning the financial information of SC Health and Rockley UK is incorporated herein by reference. In addition, the disclosures contained in the Registration Statement in the sections titled SC Healths Managements Discussion and Analysis of Financial Condition and Results of Operations beginning on page 194 of the Registration Statement and Rockleys Managements Discussion and Analysis of Financial Condition and Results of Operations of Rockley UK beginning on page 222 of the Registration Statement, and in the section titled Managements Discussion and Analysis of Financial Condition and Results of Operations in the HoldCo 10-Q, are incorporated herein by reference.
10
Properties
The disclosure contained in the Registration Statement in the section titled Information About Rockley Facilities beginning on page 221 of the Registration Statement is incorporated herein by reference.
Security Ownership of Certain Beneficial Owners and Management
The following table sets forth information regarding the beneficial ownership of HoldCo ordinary shares immediately following the Business Combination by:
|
each person who is known to be the beneficial owner of more than 5% of HoldCos ordinary shares; |
|
each of HoldCos current executive officers and directors; and |
|
all executive officers and directors of HoldCo as a group. |
Beneficial ownership is determined according to the rules of the SEC, which generally provide that a person has beneficial ownership of a security if he, she or it possesses sole or shared voting or investment power over that security, including options, warrants, and other similar instruments that are currently exercisable or exercisable within 60 days, but does not include any other HoldCo ordinary shares issuable upon the exercise of any other outstanding options, warrants or similar instruments held by other persons. The beneficial ownership percentages below are based on 126,256,257 HoldCo ordinary shares issued and outstanding as of August 11, 2021 after the Closing and do not take into account ordinary shares issuable upon the exercise of warrants to purchase up to approximately 14,204,266 ordinary shares that remain outstanding after the Closing.
Unless otherwise indicated, and subject to applicable community property laws, HoldCo believes that all persons named in the table have sole voting and investment power with respect to all ordinary shares beneficially owned by them.
Name and Address of Beneficial Owner (1) |
Number of Shares
Beneficially Owned |
Percentage | ||||||
5% Holders: |
||||||||
SC Health Group Limited (2) |
9,237,500 | 7.3 | % | |||||
Hengtong Optic-Electric International Co. Limited |
6,949,317 | 5.5 | % | |||||
Executive Officers and Directors: |
||||||||
Andrew Rickman (3) |
17,462,734 | 13.8 | % | |||||
Mahesh Karanth (4) |
1,262,791 | 1.0 | % | |||||
Amit Nagra (5) |
1,771,042 | 1.4 | % | |||||
William Huyett |
| | ||||||
Brian Blaser |
| | ||||||
Caroline Brown (6) |
62,085 | * | ||||||
Karim Karti |
| | ||||||
Michele Klein |
| | ||||||
Pamela Puryear |
| | ||||||
All directors and executive officers as a group (nine individuals) (7) |
20,558,652 | 15.9 | % |
* |
Less than 1% |
(1) |
Unless otherwise noted, the business address of each of those listed in the table above is 3rd Floor 1 Ashley Road, Altrincham, Cheshire, United Kingdom, WA14 2DT. |
(2) |
SC Health Group Limited wholly owns each of the Sponsor and SC Health II Limited. Each of SC Health Group Limited and David Sin may be deemed to beneficially own the shares held by the Sponsor and SC Health II Limited by virtue of their direct and indirect ownership, respectively, of the shares of SC Health Holdings Limited and SC Health II Limited. Each of SC Health Group Limited and David Sin disclaims beneficial ownership over any securities owned by the Sponsor and SC Health II Limited other than to the extent of any of their respective pecuniary interest therein, directly or indirectly. The beneficial ownership information reflects the transfer by the Sponsor of 1,250,000 founder shares to unrelated third parties to facilitate the financing of the Sponsor-affiliated entities purchase in the PIPE Financing. Such entities entered into financing arrangements with unrelated third parties in exchange for the transfer of and a security interest in, the HoldCo ordinary shares (including shares to be purchased in the PIPE Financing) and HoldCo warrants of the Sponsor-affiliated entities. To the extent any such shares are provided as collateral, such third parties may have dispositive power over such pledged shares but would not have voting power unless and until such shares are sold or forfeited under such financing arrangements. In addition, Sponsor-affiliated entities have agreed to transfer shares held by such entities to Dr. Rickman in exchange for Dr. Rickmans making available up to 6.0 million of his HoldCo ordinary shares to facilitate the Sponsors financing of its PIPE subscription commitment, with the number of shares to be transferred to be based on the price performance of HoldCo ordinary shares. Subject to the terms of the Sponsor PIPE financings, the Sponsor could cease to beneficially own any HoldCo equity. |
(3) |
Dr. Rickman has pledged up to 6.0 million of his HoldCo ordinary shares to facilitate the Sponsors financing of its PIPE subscription commitment, which, if forfeited in their entirety, would reduce his estimated beneficial ownership by approximately 4%. The lender may have dispositive power over such pledged shares but would not have voting power unless and until such shares are forfeited to the lender. In addition, |
11
Sponsor-affiliated entities have agreed to transfer shares held by such entities to Dr. Rickman in exchange for Dr. Rickmans making available up to 6.0 million of his HoldCo ordinary shares to facilitate the Sponsors financing of its PIPE subscription commitment, with the number of shares to be transferred to be based on the price performance of HoldCo ordinary shares. The disclosure in the in the Registration Statement in the section titled Proposal No. 1 BCA Proposal Related Agreements PIPE Subscription Agreements on pages 131 to 132 of the Registration Statement is incorporated herein by reference. |
(4) |
Includes 1,257,271 ordinary shares subject to options held by Mr. Karanth exercisable within 60 days of August 11, 2021. |
(5) |
Includes 1,737,779 ordinary shares subject to options held by Mr. Nagra exercisable within 60 days of August 11, 2021. |
(6) |
Represents 62,085 ordinary shares subject to options held by Dr. Brown exercisable within 60 days of August 11, 2021. |
(7) |
Includes 3,057,135 ordinary shares subject to options held by our current directors and executive officers exercisable within 60 days of August 11, 2021. |
Directors and Executive Officers
General
The disclosures concerning the executive officers and directors of HoldCo included in the Registration Statement in the sections titled Management of HoldCo Following the Business Combination beginning on page 244 of the Registration Statement and Executive Compensation of Rockley beginning on page 260 of the Registration Statement, and in Item 5.02 of this Current Report are incorporated herein by reference.
Upon the consummation of the Business Combination, each director and executive officer of SC Health ceased serving in such capacities.
The following table sets forth certain information regarding the HoldCo directors and executive officers effective upon the Closing:
Name |
Age |
Position |
||
Executive Officers | ||||
Andrew Rickman, OBE | 61 | Chairman and Chief Executive Officer | ||
Mahesh Karanth | 59 | Chief Financial Officer | ||
Amit Nagra, PhD | 48 | Chief Operating Officer | ||
Non-Employee Director Nominees | ||||
William Huyett (1)(2) | 65 | Lead Independent Director | ||
Brian Blaser (1) | 56 | Director | ||
Caroline Brown, PhD (1)(3) | 59 | Director | ||
Karim Karti (3) | 52 | Director | ||
Michele Klein (2)(3) | 71 | Director | ||
Pamela Puryear (2) (3) | 57 | Director |
(1) | Member of the audit committee. | |
(2) | Member of the compensation committee. | |
(3) | Member of the nominating and corporate governance committee. |
Directors
In connection with the Closing, the size of the HoldCo board of directors was increased from one member to seven members. Dr. Rickman served as the sole director of HoldCo prior to the Closing and remained as a director of HoldCo after the Closing. Effective upon the Closing on August 11, 2021, the following additional individuals were appointed to the HoldCo board of directors:
William Huyett
Brian Blaser
Caroline Brown, PhD
Karim Karti
Michele Klein
Pamela Puryear
12
Effective upon the Closing, the HoldCo board of directors was divided into three classes, Class I, Class II, and Class III, with members of each class serving staggered three-year terms. The HoldCo board of directors was divided into the following classes:
|
Class I, which consists of Brian Blaser and Pamela Puryear, whose terms will expire at HoldCos first annual meeting of shareholders to be held after the completion of the Business Combination; |
|
Class II, which consists of Karim Karti and Michele Klein, whose terms will expire at HoldCos second annual meeting of shareholders to be held after the completion of the Business Combination; and |
|
Class III, which consists of Dr. Andrew Rickman, William Huyett and Caroline Brown, whose terms will expire at HoldCos third annual meeting of shareholders to be held after the completion of the Business Combination. |
At each annual meeting of shareholders to be held after the initial classification, the successors to directors whose terms then expire will be elected to serve from the time of election and qualification until the third annual meeting following their election and until their successors are duly elected and qualified.
Director Independence and Board Committees
The HoldCo board of directors determined that each of the directors on the HoldCo board of directors other than Dr. Andrew Rickman, OBE, qualifies as an independent director, as defined under the rules of the NYSE Listed Company Manual (the NYSE listing rules), and the HoldCo board of directors consists of a majority of independent directors, as defined under the rules of the SEC and NYSE listing rules relating to director independence requirements. In addition, HoldCo is subject to the rules of the SEC and NYSE listing rules relating to the membership, qualifications, and operations of the audit committee, nominating and corporate governance committee, and compensation committee, as discussed below.
In connection with the Closing, HoldCo established an audit committee, a compensation committee and a nominating and governance committee of the HoldCo board of directors. The audit committee consists of Dr. Brown, Mr. Blaser, and Mr. Huyett, with Dr. Brown serving as chair. Dr. Brown qualifies as an audit committee financial expert, as such term is defined in Item 407(d)(5) of Regulation S-K. The compensation committee consists of Mr. Huyett, Ms. Klein, and Dr. Puryear, with Dr. Puryear serving as chair. The nominating and corporate governance committee consists of Dr. Brown, Mr. Karti, Ms. Klein, and Ms. Puryear, with Ms. Klein serving as chair.
The biographical information concerning the directors of HoldCo included in the Registration Statement in the section titled Management of HoldCo Following the Business Combination beginning on page 244 of the Registration Statement is incorporated herein by reference.
Executive Officers
Effective upon the Closing, in connection with the Business Combination, Dr. Andrew Rickman continues to serve as the Chief Executive Officer of HoldCo and Mahesh Karanth continues to serve as the Chief Financial Officer of HoldCo. Amit Nagra was appointed to serve as the Chief Operating Officer of HoldCo. The biographical information concerning the executive officers of HoldCo included in the Registration Statement in the section titled Management of HoldCo Following the Business Combination beginning on page 244 of the Registration Statement is incorporated herein by reference.
Compensation Committee Interlocks and Insider Participation
The disclosure contained in the Registration Statement under the section titled Management of HoldCo Following the Business Combination Corporate GovernanceCompensation Committee Interlocks and Insider Participation beginning on page 250 of the Registration Statement is incorporated herein by reference.
Executive Compensation
The disclosures contained in the Registration Statement in the sections titled Executive Compensation of Rockley beginning on page 260 of the Registration Statement and Director Compensation beginning on page 269 of the Registration Statement, and in Item 5.02 of this Current Report on Form 8-K are incorporated herein by reference.
Director and Executive Compensation Prior to the Business Combination
The description of the compensation of the directors and named executive officers of Rockley UK prior the consummation of the Business Combination set forth in the Registration Statement in the sections titled Executive Compensation of Rockley beginning on page 260 of the Registration Statement and Director Compensation beginning on page 269 of the Registration Statement is incorporated herein by reference.
13
Employment Agreements
The description of the compensation of the named executive officers and directors of HoldCo following the Closing is set forth in Item 5.02(e) of this Current Report and in the Registration Statement in the sections titled Executive Compensation of Rockley HoldCo Executive Compensation beginning on page 264 of the Registration Statement and Director Compensation Non-Employee Director Compensation Policy beginning on page 269 of the Registration Statement, which are incorporated herein by reference.
In connection with the Closing, HoldCo entered into employment agreements with each of Dr. Andrew Rickman, Mahesh Karanth, and Amit Nagra. A description of the employment agreements of the executive officers of HoldCo is set forth in Item 5.02(e) of this Current Report and is incorporated herein by reference. The summaries of the employment agreements are qualified in their entirety by reference to the text of such agreements, which are included as Exhibits 10.24, 10.26, 10.28, and 10.29 hereto, which is incorporated herein by reference.
Equity Plans
Additional information regarding the terms of the 2021 Plan is set forth in the Registration Statement in the section titled Proposal No. 3 Incentive Plan Proposal beginning on page 152 of the Registration Statement, which is incorporated herein by reference. That summary and the foregoing description of the 2021 Plan do not purport to be complete and are qualified in their entirety by reference to the text of the 2021 Plan, the form of which was filed as Annex H to the Registration Statement and which is filed as Exhibit 10.5 hereto, which is incorporated herein by reference.
Additional information regarding the ESPP is set forth in the Registration Statement in the section titled Proposal No. 4 ESPP Proposal beginning on page 159 of the Registration Statement, which is incorporated herein by reference. That summary and the foregoing description of the 2021 Plan do not purport to be complete and are qualified in their entirety by reference to the text of the 2021 Plan, the form of which was filed as Annex I to the Registration Statement and which is filed as Exhibit 10.7 hereto, which is incorporated herein by reference.
Director Compensation
Additional information regarding the terms of the Non-Employee Director Compensation Policy is set forth in the Registration Statement in the section titled Director Compensation beginning on page 269 of the Registration Statement, which is incorporated herein by reference. A description of the compensation of the directors of HoldCo following the Closing is set forth in Item 5.02 of this Current Report and is incorporated herein by reference. Those disclosures, including the description of the Director Compensation Policy, do not purport to be complete and are qualified in their entirety by reference to the text of the Non-Employee Director Compensation Policy, which is filed as Exhibit 10.30 hereto and is incorporated herein by reference.
Indemnification Agreement
The description of the form of indemnification agreement approved by HoldCo in connection with the Closing under Item 1.01 of this Current Report under the heading Indemnification Agreement is incorporated herein by reference. The description of the form of indemnification agreement does not purport to be complete and is qualified in its entirety by reference to the text of the form of indemnification agreement, which was filed as Exhibit 10.7 to the Registration Statement and is incorporated by reference as Exhibit 10.4 hereto, which is incorporated herein by reference.
Certain Relationships and Related Transactions, and Director Independence
The disclosures contained in the Registration Statement in the sections titled Certain Relationships and Related Person Transactions beginning on page 275 of the Registration Statement and Management of HoldCo Following the Business Combination beginning on page 244 of the Registration Statement, and under the section titled Director Independence and Board Committees below are incorporated herein by reference. In addition, the disclosures contained in Note 4 to the unaudited condensed financial statements of SC Health for the six months ended June 30, 2021 and 2020 attached as Exhibit 99.2 hereto, Note 5 to the audited financial statements of SC Health for the years ended December 31, 2020 and 2019, respectively, Note 11 to the unaudited condensed consolidated financial Statements of Rockley for the six months ended June 30, 2021 and 2020, and Note 12 to the audited consolidated financial statements of Rockley UK for the years ended December 31, 2020 and December 31, 2019, are incorporated herein by reference
14
Legal Proceedings
Neither HoldCo, Rockley UK, nor SC Health are currently subject to any material legal proceedings.
Market Price of and Dividends on the Registrants Common Equity and Related Shareholder Matters
HoldCo ordinary shares and warrants began trading on the NYSE under the symbols RKLY and RKLYW, respectively, on August 12, 2021. The disclosure in the Registration Statement in the section titled Risk Factors Risks Related to SC Health and the Business Combination There can be no assurance that the HoldCos ordinary shares will be approved for listing on the NYSE or that HoldCo will be able to comply with the continued listing standards of the NYSE beginning on page 83 of the Registration Statement is incorporated herein by reference.
The information in the section titled Market Price and Dividend Information beginning on page 47 of the Registration Statement is incorporated herein by reference. Additional information regarding holders of HoldCo securities is set forth in the section titled Description of Registrants Securities below, which is incorporated herein by reference.
HoldCo has not paid any cash dividends on its ordinary shares to date, and there are no current plans to pay cash dividends on the HoldCo ordinary shares. The declaration, amount and payment of any future dividends will be at the sole discretion of the HoldCo board of directors.
HoldCo estimates that, as of August 12, 2021, following the consummation of the Business Combination, there were approximately 384 registered holders of HoldCo ordinary shares, one registered holder of HoldCo convertible loan notes, and three registered holders of HoldCo warrants.
The disclosure contained in the Registration Statement in the section titled Material U.S. Federal Income Tax Considerations beginning on page 164 of the Registration Statement is incorporated herein by reference.
Recent Sales of Unregistered Securities
The disclosure set forth under the Introductory Note and Item 3.02 of this Current Report relating the issuance of HoldCo ordinary shares to Subscribers in the PIPE is incorporated herein by reference.
Description of Registrants Securities to be Registered
The description of HoldCos securities contained in the Registration Statement in the sections titled Description of HoldCo Securities beginning on page 281 of the Registration Statement and Comparison of the Rights of Holders of SC Health Class A Ordinary Shares and HoldCo Ordinary Shares beginning on page 288 of the Registration Statement is incorporated herein by reference.
Indemnification of Directors and Officers
The disclosure contained in the Registration Statement in Item 20. Indemnification of Directors and Officers beginning on page II-1 of the Registration Statement is incorporated herein by reference. In addition, the disclosure under Item 1.01 of this Current Report under the section titled Indemnification Agreement and the description of the form of indemnification agreement included under Item 5.02 of this Current Report under the heading Indemnification Agreement are incorporated herein by reference. Those disclosures and the description of the form of indemnification agreement do not purport to be complete and are qualified in their entirety by reference to the text of the form of indemnification agreement, which was filed as Exhibit 10.7 to the Registration Statement and is incorporated by reference as Exhibit 10.4 hereto, which is incorporated herein by reference.
Financial Statements and Supplementary Data
The disclosure set forth under Item 9.01 of this Current Report on Form 8-K is incorporated herein by reference.
Changes in and Disagreements with Accountants on Accounting and Financial Disclosure
The disclosure set forth under Item 4.01 of this Current Report on Form 8-K is incorporated herein by reference.
Financial Statements and Exhibits
The disclosure set forth under Item 9.01 of this Current Report on Form 8-K is incorporated herein by reference.
15
Item 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant.
Prior to the Business Combination, Rockley UK was party to a $35.0 million term loan facility dated September 29, 2020, as amended from time to time, with Rockley UK, as borrower, Rockley Photonics Inc., as guarantor, Credit Suisse International as agent and security agent and SIG-i Capital AG as arranger (the SIG-I Facility). In connection with the Business Combination, the Loan Facility was amended on June 28, 2021 to permit a novation of the facility to HoldCo at the effective time of the Scheme and to permit a conversion of 30% of the debt thereunder to ordinary shares of HoldCo at the time the Business Combination, with a 90-day lock-up applying to such shares. The term of the remaining facility was also extended to August 31, 2022. Rockley UK will remain a guarantor under the amended SIG-I Facility going forward.
The amended SIG-I Facility contains standard events of default, including failure to pay, non-compliance with obligations under the facility agreement, misrepresentation, cross-default in relation to Financial Indebtedness of £250,000 or more (or its equivalent in other currencies), insolvency or insolvency proceedings, unlawfulness, repudiation, a judgment is rendered for an amount of at least £250,000 (or its equivalent in other currencies), revocation of a government approval that would have a material adverse effect, validity of the agreement and cessation of business. In addition, a failure of HoldCo to issue fully paid-up shares to the Lender or Lender designate as part of the Business Combination would also be an event of default under the amended SIG-I Facility. Upon any event of default which is continuing, the majority lenders could accelerate the facility and all the outstanding balance shall be immediately due and payable. Upon an insolvency event of default, the majority lenders are entitled to declare the product of 125% of the principal amount plus any interest accrued as immediately due and payable.
The disclosure contained in the Registration Statement in the section titled Unaudited Pro Forma Condensed Combined Financial Information Other Events in Connection with the Business Combination beginning on page 180 of the Registration Statement is incorporated herein by reference.
That disclosure and the foregoing description of the amended SIG-I Facility do not purport to be complete and are qualified in their entirety by reference to the text of the amended SIG-I Facility filed as Exhibit 10.23 hereto and incorporated herein by reference.
Item 3.02. Unregistered Sales of Equity Securities.
The disclosure set forth in the Introductory Note above is incorporated by reference into this Item 3.02
PIPE Financing
In connection with the Business Combination, on March 19, 2021, HoldCo and SC Health entered into the Subscription Agreements with the Subscribers (including entities affiliated with the Sponsor), SC Health and HoldCo, pursuant to which the Subscribers agreed to purchase the PIPE Shares for a purchase price of $10.00 per share in the PIPE or an aggregate purchase price of $150 million.
At the closing of the PIPE immediately prior to the Merger Effective Time, the Subscribers purchased 15,000,000 PIPE Shares for an aggregate purchase price of approximately $150 million, of which subscribers affiliated with the Sponsor purchased an aggregate of 5,000,000 shares for $50 million. At the Closing, the PIPE Shares were issued pursuant to an exemption under Section 4(a)(2) of the Securities Act.
Pursuant to the Subscription Agreements, HoldCo agreed that, if HoldCo ordinary shares issuable to the Subscribers in exchange for their PIPE Shares are not registered in connection with the Business Combination, within 30 calendar days after the Closing, HoldCo will file with the SEC (at HoldCos sole cost and expense) a registration statement registering the resale of the PIPE Shares received by the Subscribers in connection with the Business Combination (the Resale Registration Statement), and HoldCo shall use its commercially reasonable efforts to have the Resale Registration Statement declared effective no later than 90 days after the Closing (or 120 days if the SEC reviews the Resale Registration Statement) or 10 days after the SEC notifies HoldCo that it will not review the Resale Registration Statement; provided, however, that HoldCos obligations to include the PIPE Shares held by a Subscriber in the Resale Registration Statement will be contingent upon the respective Subscriber furnishing in writing, to HoldCo, such information regarding the Subscriber, the securities of HoldCo held by such Subscriber and the intended method of disposition of the shares, as shall be reasonably requested by HoldCo to effect the registration of such shares, and will execute such documents in connection with such registration, as HoldCo may reasonably request, which will be what is customary of a selling shareholder in similar situations.
16
HoldCo will also be required to use its commercially reasonable efforts to cause the Resale Registration Statement to become effective and to maintain the effectiveness of the Resale Registration Statement until the earliest of (a) the date on which all of the PIPE Shares may be sold without restriction as to the manner and amount of sales under Rule 144, (b) the date on which the Subscribers cease to hold any PIPE Shares acquired pursuant to the Business Combination, and (c) the second anniversary of the Closing.
HoldCo is entitled to delay, postpone or suspend the effectiveness of the Resale Registration Statement under certain circumstances, including, but not limited to, if an event has occurred that the HoldCo board of directors reasonably believes would require additional disclosure by HoldCo in the Resale Registration Statement of material non-public information. However, HoldCo may not delay or suspend the Resale Registration Statement on more than two occasions for more than 60 consecutive days, or more than 90 total days, in each case during any 12-month period.
This summary does not purport to be complete and is qualified in its entirety by reference to the text of the forms of Subscription Agreements filed as Exhibits 10.4 and 10.5 to the Registration Statement and incorporated by reference as Exhibits 10.1 and 10.2 hereto, which is incorporated herein by reference.
The disclosure set forth under the Introductory Note relating the issuance of HoldCo ordinary shares to Subscribers in the PIPE is incorporated herein by reference.
SIG-I Facility
The information set forth under Item 2.03 of this Current Report with respect to the SIG-I Facility is incorporated herein by reference. Such information, including the description of the amended SIG-I Facility, does not purport to be complete and is qualified in its entirety by reference to the text of the amended SIG-I Facility filed as Exhibit 10.23 hereto and incorporated herein by reference.
Item 3.03. Material Modification to Rights of Security Holders.
HoldCo Articles
On August 11, 2021, in connection with the Closing, the amended and restated Memorandum and Articles of Association of the Company (the HoldCo Articles) became effective.
The disclosure contained in the Registration Statement in the sections titled Description of HoldCo Securities beginning on page 281 of the Registration Statement and Comparison of the Rights of Holders of SC Health Class A Ordinary Shares and HoldCo Ordinary Shares beginning on page 288 of the Registration Statement is incorporated herein by reference.
This summary does not purport to be complete and is qualified in its entirety by reference to the text of the amended and restated memorandum and articles of association of HoldCo, which is included as Exhibit 3.1 hereto and incorporated herein by reference.
Warrant Amendment
In connection with the Closing, on August 11, 2021, SC Health, HoldCo and Computershare, as warrant agent, entered into the HoldCo Warrant Agreement. The disclosure contained in Item 1.01 of this Current Report under the heading Warrant Amendment, is incorporated herein by reference. That disclosure, including the foregoing descriptions of the HoldCo Warrant Agreement and the SC Health Warrant Agreement, is qualified in its entirety by reference to the text of the HoldCo Warrant Agreement filed as Exhibit 4.2 and the SC Health Warrant Agreement which was filed as Exhibit 4.1 to the Registration Statement and incorporated by reference as Exhibit 4.2 and Exhibit 4.1, respectively, which are incorporated herein by reference.
Item 4.01. Changes in Registrants Certifying Accountant.
As previously disclosed, on August 11, 2021, HoldCo, Rockley UK, and SC Health consummated the Business Combination, as a result of which each of Rockley UK and SC Health became a wholly owned subsidiary of HoldCo (or the Company), and the Company became the holding company of the combined group listed on the NYSE.
On August 11, 2021, HoldCo engaged Ernst & Young LLP (EY) as the independent registered public accounting firm of the Company and its subsidiaries in connection with the Companys consolidated financial statements for the year ended December 31, 2021. The engagement of EY was approved by the audit committee of the board of directors of the Company. EY currently also serves as the independent registered public accounting firm of Rockley UK. Accordingly, WithumSmith+Brown, PC (Withum), SC Healths
17
independent registered public accounting firm prior to the closing of the Business Combination, was informed that it would be dismissed as SC Healths independent registered public accounting firm effective as of August 11, 2021.
The audit reports of Withum on the financial statements of SC Health as of December 31, 2020 and 2019 and for the period from December 10, 2018 (inception) through December 31, 2018 did not contain any adverse opinion or disclaimer of opinion, nor were they qualified or modified as to uncertainty, audit scope or accounting principles except as follows: such audit report contained an explanatory paragraph in which Withum expressed substantial doubt as to SC Healths ability to continue as a going concern.
During the years ended December 31, 2019 and 2020 and the subsequent interim period preceding such dismissal (including the six months ended June 30, 2021), there were no disagreements (as defined in Item 304(a)(iv) of Regulation S-K) between SC Health and Withum on any matter of accounting principles or practices, financial disclosure or auditing scope or procedure, which disagreements, if not resolved to the satisfaction of Withum, would have caused it to make reference to the subject matter of the disagreements in its reports on SC Healths financial statements for such period.
During the years ended December 31, 2019 and 2020 and the subsequent interim period preceding such dismissal (including the six months ended June 30, 2021), there were no reportable events (as defined in Item 304(a)(1)(v) of Regulation S-K).
During the years ended December 31, 2019 and 2020 and the subsequent interim period preceding such dismissal (including the six months ended June 30, 2021), neither SC Health nor anyone on its behalf consulted EY regarding either (i) the application of accounting principles to a specified transaction, either completed or proposed, or the type of audit opinion that might be rendered on SC Healths financial statements, and neither a written report nor oral advice was provided to SC Health that EY concluded was an important factor considered by SC Health in reaching a decision as to any accounting, auditing or financial reporting issue, or (ii) any matter that was either the subject of a disagreement or a reportable event, as defined in Items 304(a)(1)(iv) and 304(a)(1)(v) of Regulation S-K, respectively.
HoldCo has provided Withum with a copy of the foregoing disclosures and has requested that Withum furnish it with a letter addressed to the U.S. Securities and Exchange Commission stating whether it agrees with the statements set forth above and, if not, stating the respects in which it does not agree. A copy of Withums letter, dated August 16, 2021, is filed as Exhibit 16.1 to this Current Report.
Item 5.01. Changes in Control of Registrant.
The disclosure in the Registration Statement in the section titled Proposal No. 1 the BCA Proposal beginning on page 104 of the Registration Statement is incorporated herein by reference. Further, the disclosure contained in the Introductory Note and Item 2.01 of this Current Report is incorporated herein by reference.
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
The information set forth in the section titled Form 10 Information under the captions Directors and Executive Officers and Certain Relationships and Related Party Transactions in Item 2.01 of this Current Report is incorporated herein by reference. The disclosure set forth in the Registration Statement in the section titled Management of HoldCo Following the Business Combination beginning on page 244 of the Registration Statement is incorporated herein by reference.
(d)
Upon the Closing on August 11, 2021, the following individuals were appointed to the HoldCo board of directors:
William Huyett
Brian Blaser
Caroline Brown, PhD
Karim Karti
Michele Klein
Pamela Puryear
The directors listed above are eligible to receive compensation for their services as non-employee directors under the Companys Director Compensation Policy. The disclosure set forth under Item 1.01 of this Current Report under the captions Non-Employee Director Compensation Policy and Indemnification Agreement and in the section titled Form 10 Information under the captions Directors and Executive Officers, - Director Independence and Board Committees, Executive Compensation, Security Ownership of Certain Beneficial Owners and Management, and Certain Relationships and Related Transactions, and Director Independence in Item 2.01 of this Current Report regarding the committees to which each such director has been appointed, any information required by Item 404(a) of Regulation S-K (404 Transactions), and any material plan, contract or arrangement to which the director is a party or in which such director participates, is incorporated herein by reference. There are no 404 Transactions between HoldCo and any of the directors listed above.
18
(e)
In connection with and following the Closing, HoldCo entered into employment agreements with the following executive officers, which agreements superseded and restated each named executive officers prior employment and compensation arrangements. In connection with such agreements, each executive officer waived any entitlement to accelerated vesting under the terms of their respective option award agreements with respect to the Business Combination.
Andrew Rickman, OBE
HoldCo entered into an employment agreement amendment with Dr. Rickman, pursuant to which Dr. Rickman will serve as the chief executive officer of HoldCo and will report directly to the board of directors of HoldCo. Dr. Rickmans employment with HoldCo will continue until terminated in accordance with its terms.
Under the employment agreement amendment, among other terms, Dr. Rickman is entitled to receive an initial annual base salary of $500,000, which will be subject to increase at the discretion of the board of directors of HoldCo or the Compensation Committee thereof and to be eligible to receive an annual performance bonus targeted at 100% of Dr. Rickmans then current annual base salary. The actual amount of any such bonus will be determined by reference to the attainment of applicable HoldCo and/or individual performance objectives, as determined by the board of directors of HoldCo or the Compensation Committee.
Dr. Rickman will also be eligible to participate in the customary health, welfare, and fringe benefit plans provided by HoldCo to its employees.
In addition, HoldCo entered into a side letter pursuant to which Dr. Rickman will be eligible to receive equity awards with a fair value of $5.0 million, determined at HoldCos board of directors discretion either on the date of grant or on the Closing, and weighted equally between (i) stock options to purchase HoldCo ordinary shares at a price equal to such stocks fair market value at grant and (ii) restricted stock units (RSUs), in each case under the 2021 Plan. Both Dr. Rickmans stock options and his RSUs would be subject to ratable vesting over four (4) years beginning on the closing of the Business Combination, subject to acceleration upon involuntary termination in connection with a change in control, as defined in the 2021 Plan. Upon the Closing, Dr. Rickman received the above referenced stock options, which stock option will become exercisable (to the extent vested) only after the shares underlying such options are registered on an applicable Form S-8 registration statement and shall not be exercisable before such date.
Under his employment agreement amendment, HoldCo must provide Dr. Rickman at least twelve months notice, or pay in lieu of notice, prior to any termination of his employment unless that termination is for cause (as defined under his employment agreement amendment). Dr. Rickman must provide HoldCo with at least twelve months notice prior to his resignation, unless HoldCo reasonably determines that such resignation is for good reason (as defined in his employment agreement amendment).
If Dr. Rickmans employment is terminated by HoldCo without cause, or by Dr. Rickman for good reason, subject to his execution and non-revocation of a release of claims and continued compliance with his confidentiality and non-solicitation requirements, then, in addition to any accrued amounts, Dr. Rickman will be entitled to receive the following severance payments and benefits: (i) an amount equal to the sum of (a) his annual base salary then in effect and (b) 100% of his target annual bonus amount, payable in equal instalments over one year and reduced by any basic salary paid in lieu of notice; and (ii) continuation of all benefits for a period of twelve months.
The employment agreement amendment contains non-competition and non-solicitation and confidentiality provisions which, among other restrictions, and except in the case of an involuntary termination, restrict Dr. Rickmans ability to be engaged or employed by, undertake duties for or be otherwise interested in HoldCos competitors, customers or suppliers, for a period of twelve (12) months following his termination (reduced by any portion of Dr. Rickmans pre-termination notice period during which time he is not providing services, or garden leave).
Mahesh Karanth
HoldCo entered into an employment agreement with Mr. Karanth, pursuant to which Mr. Karanth will serve as the chief financial officer of HoldCo and will report directly to HoldCos chief executive officer. Mr. Karanths service pursuant to the employment agreement will continue until terminated in accordance with its terms. Under the employment agreement, Mr. Karanth will receive an initial annual base salary of $450,000, which will be subject to increase at the discretion of the board of directors of HoldCo or the Compensation Committee thereof and will be eligible to receive an annual performance bonus targeted at 60% of Mr. Karanths then-current annual base salary. The actual amount of any such bonus will be determined by reference to the attainment of applicable company and/or individual performance objectives, as determined by the board of directors of HoldCo or the Compensation Committee thereof.
19
Pursuant to his employment agreement, Mr. Karanth will also be eligible to participate in the customary health, welfare, and fringe benefit plans provided by HoldCo to its employees.
In addition, pursuant his employment agreement, Mr. Karanth will be eligible to receive equity awards with a fair value of $2.0 million, determined at HoldCos board of directors discretion either on the date of grant or on the Closing, and weighted equally between (i) stock options to purchase HoldCo ordinary shares at a price equal to such stocks fair market value at grant and (ii) RSUs, in each case under the 2021 Plan. Both Mr. Karanths stock options and his RSUs would be subject to ratable vesting over four (4) years beginning on the closing of the Business Combination, subject to acceleration upon involuntary termination in connection with a change in control, as defined in the 2021 Plan. Upon the Closing, Mr. Karanth received the above referenced stock options, which stock option will become exercisable (to the extent vested) only after the shares underlying such options are registered on an applicable Form S-8 registration statement and shall not be exercisable before such date.
If Mr. Karanths employment is terminated by HoldCo without cause, or by Mr. Karanth for good reason (each, as defined in his employment agreement), subject to his execution and non-revocation of a general release of claims in our favor and continued compliance with customary confidentiality and non-solicitation requirements, then, in addition to any accrued amounts, Mr. Karanth will be entitled to receive the following severance payments and benefits: (i) an amount equal to the sum of (a) six (6) months of his annual base salary then in effect and (b) 50% of his target annual bonus amount, payable in equal installments over six months; and (ii) payment of premiums for continued healthcare coverage under the Consolidated Omnibus Budget Reconciliation Act of 1985 (COBRA) for up to six (6) months after the termination date.
The employment agreement contains customary confidentiality and non-solicitation provisions, and also will include a best pay provision under Section 280G of the Code, pursuant to which any parachute payments that become payable to Mr. Karanth will either be paid in full or reduced so that such payments are not subject to the excise tax under Section 4999 of the Code, whichever results in the better after-tax treatment to Mr. Karanth.
Amit Nagra, PhD
HoldCo entered into an employment agreement with Dr. Nagra, pursuant to which Dr. Nagra will serve as the chief operating officer of HoldCo and will report directly to HoldCos chief executive officer. Dr. Nagras service pursuant to the employment agreement will continue until terminated in accordance with its terms. Under the employment agreement, Dr. Nagra will receive an initial annual base salary of $450,000, which will be subject to increase at the discretion of the board of directors or the Compensation Committee thereof and will be eligible to receive an annual performance bonus targeted at 60% of Dr. Nagras then-current annual base salary. The actual amount of any such bonus will be determined by reference to the attainment of applicable company and/or individual performance objectives, as determined by the board of directors of HoldCo or the Compensation Committee thereof.
Pursuant to the employment agreement, Dr. Nagra will also be eligible to participate in the customary health, welfare, and fringe benefit plans, provided by HoldCo to its employees.
In addition, pursuant to his employment agreement, Dr. Nagra will be eligible receive equity awards with a fair value of $1.5 million, determined at the HoldCos board of directors discretion either on the date of grant or on the closing of the business combination, and weighted equally between (i) stock options to purchase HoldCo ordinary shares at a price equal to such stocks fair market value at grant and (ii) RSUs, in each case under the 2021 Plan. Both Dr. Nagras stock options and his RSUs would be subject to ratable vesting over four (4) years beginning on the closing of the Business Combination, subject to acceleration upon involuntary termination in connection with a change in control, as defined in the 2021 Plan. Upon the Closing, Dr. Nagra received the above referenced stock options, which stock option will become exercisable (to the extent vested) only after the shares underlying such options are registered on an applicable Form S-8 registration statement and shall not be exercisable before such date.
If Dr. Nagras employment is terminated by HoldCo without cause, or by Dr. Nagra for good reason (each, as defined in his employment agreement), subject to his execution and non-revocation of a general release of claims in our favor, then, in addition to any accrued amounts, Dr. Nagra will be entitled to receive the following severance payments and benefits: (i) an amount equal to the sum of (a) six months of his annual base salary then in effect and (b) 50% of his target annual bonus amount, payable in equal installments over six months; and (ii) payments of premiums for continued healthcare coverage under COBRA for up to six months after the termination date.
20
The employment agreement contains customary confidentiality and non-solicitation provisions, and also will include a best pay provision under Section 280G of the Code, pursuant to which any parachute payments that become payable to Dr. Nagra will either be paid in full or reduced so that such payments are not subject to the excise tax under Section 4999 of the Code, whichever results in the better after-tax treatment to Dr. Nagra.
The summaries of the employment agreements above are qualified in their entirety by reference to the text of such agreements, which are included as Exhibits 10.24, 10,26, 10.28, and 10.29 hereto and incorporated herein by reference.
Item 5.03. Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.
The disclosure set forth Item 3.03 of this Current Report under HoldCo Articles is incorporated herein by reference. This summary does not purport to be complete and is qualified in its entirety by reference to the text of the HoldCo Articles, which is included as Exhibit 3.1 hereto and incorporated herein by reference.
Item 5.06. Change in Shell Company Status.
As a result of the Business Combination, HoldCo ceased being a shell company. The disclosure in the Registration Statement in the section titled Proposal No. 1BCA Proposal beginning on page 104 of the Registration Statement is incorporated herein by reference. Further, the disclosure contained in Item 2.01 of this Current Report is incorporated therein by reference.
Item 8.01. Other Events
On August 11, 2021, HoldCo, Rockley UK, and SC Health announced the consummation of the Business Combination, following the approval of the Business Combination at the extraordinary general meeting of the SC Health shareholders held on August 6, 2021. A copy of the press release announcing the Closing is filed as Exhibit 99.3 hereto and is incorporated herein by reference.
Item 9.01. Financial Statements and Exhibits.
(a) |
Financial statements of businesses acquired |
The unaudited condensed consolidated financial statements of HoldCo for the period from inception (March 11, 2021) through June 30, 2021 and the related notes thereto are set forth in the HoldCo 10-Q and are incorporated herein by reference.
The unaudited condensed consolidated financial statements of Rockley UK for the six months ended June 30, 2021 and 2020 and the related notes thereto are set forth in the HoldCo 10-Q and are incorporated herein by reference.
The unaudited condensed consolidated financial statements of Rockley UK for the three months ended March 31, 2021 and 2020 and the related notes are set forth on pages F-38 through F-64 of the Registration Statement and are incorporated herein by reference.
The audited consolidated financial statements of Rockley UK for the years ended December 31, 2020 and 2019, the related notes and report of independent registered public accounting firm thereto are set forth in the Registration Statement on pages F-2 through F-37 and are incorporated herein by reference.
The unaudited consolidated financial statements of SC Health for the six months ended June 30, 2021 and 2020 and the related notes thereto are set forth in SC Healths quarterly report on Form 10-Q for the quarter ended June 30, 2021 filed on August 9, 2021 and are included herein as Exhibit 99.2 and incorporated herein by reference.
The unaudited condensed consolidated financial statements of SC Health for the three months ended March 31, 2021 and 2020 and the related notes thereto are set forth in the Registration Statement on pages F-92 through F-113 and are incorporated herein by reference.
The audited consolidated financial statements of SC Health for the year ended December 31, 2020 and December 31, 2019, the related notes and report of independent registered public accounting firm thereto are set forth in the Registration Statement on pages F-65 through F-91 and are incorporated herein by reference.
21
(b) |
Pro forma financial information |
The unaudited pro forma condensed combined financial information of the Company for the year ended December 31, 2020 are included in the Registration Statement in the section titled Unaudited Pro Forma Condensed Combined Financial Information beginning on page 179 of the Registration Statement and is incorporated herein by reference.
The unaudited pro forma condensed combined financial information of the Company as of and for the six months ended June 30, 2021 is set forth in Exhibit 99.1 hereto and is incorporated herein by reference.
22
Exhibits
EXHIBIT INDEX
23
24
|
Certain exhibits and schedules to this exhibit have been omitted pursuant to Item 601(a)(5) of Regulation S-K. The Registrant hereby agrees to furnish a copy of any omitted exhibits or schedules to the SEC upon request. |
+ |
Indicates a management contract or compensatory plan. |
25
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Rockley Photonics Holdings Limited |
||
By: | /s/ Mahesh Karanth | |
Name: |
Mahesh Karanth |
|
Title: |
Chief Financial Officer |
Date: August 16, 2021
26
Exhibit 16.1
August 16, 2021
Office of the Chief Accountant
Securities and Exchange Commission
100 F Street, NE
Washington, D.C. 20549
Ladies and Gentlemen:
We have read Rockley Photonics Holdings Limiteds (HoldCo) statements included under Item 4.01 of its Form 8-K dated August 16, 2021. We agree with the statements concerning our Firm under Item 4.01, in which we were informed of our dismissal as SC Health Corporations independent registered public accounting firm on August 11, 2021. We are not in a position to agree or disagree with other statements contained therein.
Very truly yours,
/s/ WithumSmith+Brown, PC
New York, New York
Exhibit 99.1
UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION
Defined terms included below shall have the same meaning as terms defined and included elsewhere in the Current Report on Form 8-K (the Form 8-K) filed with the SEC on August 16, 2021
Introduction
We are providing the following unaudited pro forma condensed combined financial information to aid you in your analysis of the financial aspects of the Business Combination. The unaudited pro forma condensed combined financial information should be read in conjunction with the accompanying notes.
The unaudited pro forma condensed combined balance sheet as of June 30, 2021 combines the historical unaudited balance sheet of SC Health as of June 30, 2021 with the historical unaudited consolidated balance sheet of Rockley as of June 30, 2021, giving effect to the Business Combination as if it had been consummated on that date.
The unaudited pro forma condensed combined statement of operations for the six months ended June 30, 2021 combines the historical unaudited statement of operations of SC Health for the six months ended June 30, 2021 with the historical unaudited consolidated statement of operations of Rockley for the six months ended June 30, 2021.
The unaudited pro forma condensed combined statement of operations for the fiscal year ended December 31, 2020 combines the historical audited statement of operations of SC Health for the fiscal year ended December 31, 2020 with the historical audited consolidated statement of operations of Rockley for the fiscal year ended December 31, 2020, giving effect to the Business Combination as if it had been consummated on January 1, 2020.
The unaudited pro forma condensed combined financial information was derived from and should be read in conjunction with the following historical financial statements and the accompanying notes, which are included elsewhere in this prospectus/proxy statement:
|
The historical unaudited financial statements of SC Health as and for the six months ended June 30, 2021 and audited financial statements of SC Health as of and for the fiscal year ended December 31, 2020; and |
|
The historical unaudited consolidated financial statements of Rockley as of and for the six months ended June 30, 2021 and the historical audited consolidated financial statements of Rockley as of and for the fiscal year ended December 31, 2020. |
The foregoing historical financial statements have been prepared in accordance with GAAP.
The unaudited pro forma condensed combined financial information should also be read together with SC Healths Managements Discussion and Analysis of Financial Condition and Results of Operations and Rockleys Managements Discussion and Analysis of Financial Condition and Results of Operations, and other financial information included elsewhere in this Form 8-K.
Description of the Business Combination
Pursuant to the Business Combination Agreement, Rockley shareholders, which includes shares issued to convert Rockleys convertible loan notes and warrants to equity, transferred their shares in Rockley to HoldCo, a newly formed entity. HoldCo further undertook a stock split based upon an exchange ratio to align the valuation of Rockleys shares with the valuation of the SC Healths shares. Rockley MergerSub Limited (MergerSub), another newly formed entity and a wholly owned subsidiary of HoldCo, will merge with SC Health, with SC Health surviving the merger. All SC Healths ordinary shares outstanding immediately after the merger with Merger Sub were exchanged with HoldCo for the right to receive HoldCo ordinary shares and HoldCo becomes a public company.
The aggregate merger consideration for Rockley received was 114,811,411 HoldCo ordinary shares at a deemed value of $10 per share for an aggregate merger consideration of $1,148.1 million.
Accounting for the Business Combination
The Business Combination is accounted for as a forward recapitalization in accordance with GAAP. Under this method of accounting, SC Health has been treated as the acquired company for financial reporting purposes. This determination was primarily based on current shareholders of Rockley having a relative majority of the voting power of the combined entity, and as such, having the power to appoint a majority of the member of HoldCos board of directors, the operations of Rockley prior to the acquisition comprising the only ongoing operations of the combined entity and senior management of Rockley comprising the majority of the senior management of the combined entity. Accordingly, for accounting purposes, the financial statements of the combined entity will represent a continuation of the financial statements of Rockley with the acquisition being treated as the equivalent of Rockley issuing stock for the net assets of SC Health, accompanied by a recapitalization. The net assets of SC Health will be stated at historical cost, with no goodwill or other intangible assets recorded.
Other Events in Connection with the Business Combination
|
The board of directors of HoldCo approved and implemented a director compensation program for HoldCos non-employee directors (the Director Compensation Program). Under the Director Compensation Program, and following the filing of a registration statement on Form S-8 with respect to the 2021 Plan, HoldCo expects to grant (i) an Initial RSU Award to each non-employee director in connection with the closing of the Business Combination and (ii) an Annual RSU Award following the conclusion of each regular annual meeting of HoldCos shareholders commencing with the 2022 annual meeting, to each non-employee director who continues serving as a member of HoldCos board of directors. In addition, each eligible non-employee director will receive an annual cash retainer in connection with their service on HoldCos board of directors and respective committees. For additional information, including size of any cash retainers, and the size and vesting terms of the Initial RSU Award and Annual RSU Award, see Executive CompensationDirector Compensation. |
|
Following the filing of a registration statement on Form S-8 with respect to the 2021 Plan, the board of directors of HoldCo is also expected to approve grants of stock options and RSU awards to select members of the management team. For additional information, including the size and vesting terms application to these awards, see Executive CompensationHoldCo Executive Compensation. |
|
In addition, HoldCo entered into new employment agreements with its executive officers, including its named executive officers. The terms of these new employment agreements, including compensation, have been prepared as to form but remain subject to change. Accordingly, the effect of the new employment arrangements with HoldCos executive officers has been included in the unaudited pro forma condensed combined financial information. For additional information, see Executive CompensationHoldCo Executive CompensationExecutive Employment ArrangementsPost-Closing Agreements. |
|
All of the Rockley issued and outstanding convertible loan notes (other than certain convertible notes issued in connection with Rockleys term facility with Argentum Securities Ireland plc), inclusive of interest accrued thereon, converted into ordinary shares of HoldCo at a conversion price of $10.00 per share, and outstanding options exercisable for Rockley ordinary shares will rollover into options exercisable for HoldCo ordinary shares. On May 25, 2021, Rockley entered into an agreement in principle to amend the payment and maturity terms of the Argentum term facility such that 30% of the outstanding principal balance is expected to be converted to ordinary shares of HoldCo at the time of the Business Combination and 70% which would otherwise be redeemable after the closing of the Business Combination is expected to mature on August 31, 2022. For additional information, see Rockleys Managements Discussion and Analysis of Financial Condition and Results of OperationsBusiness Combination and Public Company Costs and Note 16 to the notes to the condensed consolidated financial statements of Rockley Photonics Limited. |
The adjustments in the unaudited pro forma condensed combined financial information have been identified and presented to provide relevant information necessary for an accurate understanding of the combined entity at closing of the Business Combination.
The unaudited pro forma condensed combined financial information is for illustrative purposes only. The financial results may have been different had the companies always been combined. You should not rely on the unaudited pro forma condensed combined financial information as being indicative of the historical results that would have been achieved had the companies always been combined or the future results that the combined entity will experience. SC Health and Rockley have not had any historical relationship prior to the transactions. Accordingly, no pro forma adjustments were required to eliminate activities between the companies.
Unaudited Pro Forma Condensed Combined Balance Sheet
As of June 30, 2021
(in thousands, except share and per share amounts)
SC Health | Rockley |
Transaction
Accounting Adjustments |
Ref |
Pro Forma
Combined |
||||||||||||||
Assets |
||||||||||||||||||
Current assets |
||||||||||||||||||
Cash and cash equivalents |
35 | $ | 35,395 | $ | 130,788 | A | $ | 166,218 | ||||||||||
Accounts receivable |
| 2,411 | | 2,411 | ||||||||||||||
Other receivable |
| 23,037 | | 23,037 | ||||||||||||||
Prepaid expenses |
48 | 7,724 | | 7,772 | ||||||||||||||
Other current assets |
| 258 | | 258 | ||||||||||||||
|
|
|
|
|
|
|
|
|||||||||||
Total current assets |
83 | 68,825 | 130,788 | 199,696 | ||||||||||||||
Property, equipment and finance lease right-of-use assets, net |
| 8,170 | | 8,170 | ||||||||||||||
Equity method investments |
| 4,711 | | 4,711 | ||||||||||||||
Intangible assets |
| 3,048 | | 3,048 | ||||||||||||||
Cash and marketable securities held in trust account |
93,839 | | (93,839 | ) | C | | ||||||||||||
Other non-current assets |
| 11,715 | (8,427 | ) | E | 3,288 | ||||||||||||
|
|
|
|
|
|
|
|
|||||||||||
Total assets |
93,922 | $ | 96,469 | $ | 28,522 | $ | 218,913 | |||||||||||
|
|
|
|
|
|
|
|
|||||||||||
Liabilities |
| |||||||||||||||||
Accounts payable and accrued expenses |
1,005 | $ | 20,796 | $ | (4,875 | ) | F | $ | 16,926 | |||||||||
Long-term debt, current portion |
| | 12,500 | J | 12,500 | |||||||||||||
Other current liabilities |
1,035 | 1,020 | (1,035 | ) | K | 1,020 | ||||||||||||
|
|
|
|
|
|
|
|
|||||||||||
Total current liabilities |
2,040 | 21,816 | 6,590 | 30,446 | ||||||||||||||
Long-term debt, net of current portion |
| 194,328 | (183,064 | ) | L | 11,264 | ||||||||||||
Deferred underwriting fee payable |
6,038 | | (6,038 | ) | F | | ||||||||||||
Warrant liabilities |
32,502 | | | 32,502 | ||||||||||||||
Other long-term liabilities |
| 2,719 | | 2,719 | ||||||||||||||
|
|
|
|
|
|
|
|
|||||||||||
Total liabilities |
40,580 | 218,863 | (182,512 | ) | 76,931 | |||||||||||||
Class A ordinary shares subject to redemption |
48,342 | | (48,342 | ) | M | | ||||||||||||
Shareholders Equity |
||||||||||||||||||
Ordinary shares |
| | | N | | |||||||||||||
Class A ordinary shares |
| | | N | | |||||||||||||
Class B ordinary shares |
| | | N | | |||||||||||||
Additional paid-in capital |
30,382 | 205,823 | 233,994 | N | 470,199 | |||||||||||||
Accumulated deficit |
(25,382 | ) | (328,217 | ) | 25,382 | O | (328,217 | ) | ||||||||||
|
|
|
|
|
|
|
|
|||||||||||
Total shareholders equity |
5,000 | $ | (122,394 | ) | $ | 259,376 | $ | 141,982 | ||||||||||
|
|
|
|
|
|
|
|
|||||||||||
Total liabilities and shareholders equity |
93,922 | $ | 96,469 | $ | 28,522 | $ | 218,913 | |||||||||||
|
|
|
|
|
|
|
|
See the accompanying notes to the unaudited pro forma condensed combined financial statements.
Unaudited Pro Forma Condensed Combined Statement of Operations
For the Six Months Ended June 30, 2021
(in thousands, except share and per share amounts)
SC Health | Rockley |
Transaction
Accounting Adjustments |
Ref |
Pro Forma
Combined |
Ref | |||||||||||||||||||
Revenue |
$ | | $ | 3,966 | $ | | 3,966 | |||||||||||||||||
Cost of revenue |
| 8,283 | | 8,283 | ||||||||||||||||||||
|
|
|
|
|
|
|
|
|||||||||||||||||
Gross profit |
| (4,317 | ) | | (4,317 | ) | ||||||||||||||||||
Selling, general and administrative expenses |
1,066 | 14,020 | 198 | a | ||||||||||||||||||||
1,256 | b | |||||||||||||||||||||||
754 | c | 17,294 | ||||||||||||||||||||||
Research and development |
| 33,531 | 331 |
|
b
|
|
33,862 | |||||||||||||||||
|
|
|
|
|
|
|
|
|||||||||||||||||
Operating loss |
(1,066 | ) | (51,868 | ) | (2,539 | ) | (55,473 | ) | ||||||||||||||||
Interest income (expense), net |
9 | (326 | ) | (9 | ) | d | (326 | ) | ||||||||||||||||
Other income |
| 2,860 | | 2,860 | ||||||||||||||||||||
Equity method investment loss |
| (760 | ) | | (760 | ) | ||||||||||||||||||
Change in fair value of debt instruments |
| (45,661 | ) | 45,661 | h | | ||||||||||||||||||
Realized and unrealized gain/loss on foreign currency |
| 631 | | 631 | ||||||||||||||||||||
Change in fair value of warrant liabilities |
(13,447 | ) | | | (13,447 | ) | ||||||||||||||||||
Gain from termination of forward purchase agreement |
2,951 | | (2,951 | ) | e | | ||||||||||||||||||
|
|
|
|
|
|
|
|
|||||||||||||||||
Income (loss) before income taxes |
(11,553 | ) | (95,124 | ) | 40,162 | (66,515 | ) | |||||||||||||||||
Income tax expense |
| 210 | | 210 | ||||||||||||||||||||
|
|
|
|
|
|
|
|
|||||||||||||||||
Net income (loss) |
$ | (11,553 | ) | $ | (95,334 | ) | $ | 40,162 | $ | (66,725 | ) | |||||||||||||
|
|
|
|
|
|
|
|
|||||||||||||||||
Net loss per share |
||||||||||||||||||||||||
Basic and diluted |
$ | (0.53 | ) | f | ||||||||||||||||||||
|
|
|||||||||||||||||||||||
Weighted average shares outstanding |
||||||||||||||||||||||||
Basic and diluted |
126,256,257 | g | ||||||||||||||||||||||
|
|
See the accompanying notes to the unaudited pro forma condensed combined financial statements.
Unaudited Pro Forma Condensed Combined Statement of Operations
For the Fiscal year Ended December 31, 2020
(in thousands, except share and per share amounts)
SC
Health (As Restated) |
Rockley |
Transaction
Accounting Adjustments |
Ref |
Pro Forma
Combined |
Ref | |||||||||||||||||
Revenue |
$ | | $ | 22,343 | $ | | 22,343 | |||||||||||||||
Cost of revenue |
| 24,240 | | 24,240 | ||||||||||||||||||
|
|
|
|
|
|
|
|
|||||||||||||||
Gross profit |
| (1,897 | ) | | (1,897 | ) | ||||||||||||||||
Selling, general and administrative expenses |
1,736 | 20,260 | 198 | a | ||||||||||||||||||
389 | b | |||||||||||||||||||||
754 | c | 23,337 | ||||||||||||||||||||
Research and development |
| 35,900 | 542 | b | 36,442 | |||||||||||||||||
|
|
|
|
|
|
|
|
|||||||||||||||
Operating loss |
(1,736 | ) | (58,057 | ) | (1,883 | ) | (61,676 | ) | ||||||||||||||
Interest income (expense), net |
644 | (189 | ) | (644 | ) | d | (189 | ) | ||||||||||||||
Equity method investment loss |
| (1,274 | ) | | (1,274 | ) | ||||||||||||||||
Change in fair value of debt instruments |
| (20,163 | ) | 20,163 | h | | ||||||||||||||||
Realized and unrealized gain/loss on foreign currency |
| (25 | ) | | (25 | ) | ||||||||||||||||
Change in fair value of warrant liabilities |
(5,489 | ) | | | (5,489 | ) | ||||||||||||||||
Gain from termination of forward purchase agreement |
(1,641 | ) | | 1,641 | e | | ||||||||||||||||
|
|
|
|
|
|
|
|
|||||||||||||||
Income (loss) before income taxes |
(8,222 | ) | (79,708 | ) | 19,277 | (68,653 | ) | |||||||||||||||
Income tax expense |
| 569 | | 569 | ||||||||||||||||||
|
|
|
|
|
|
|
|
|||||||||||||||
Net income (loss) |
$ | (8,222 | ) | $ | (80,277 | ) | $ | 19,277 | $ | (69,222 | ) | |||||||||||
|
|
|
|
|
|
|
|
|||||||||||||||
Net loss per share |
||||||||||||||||||||||
Basic and diluted |
$ | (0.55 | ) | f | ||||||||||||||||||
|
|
|||||||||||||||||||||
Weighted average shares outstanding |
||||||||||||||||||||||
Basic and diluted |
126,256,257 | g | ||||||||||||||||||||
|
|
See the accompanying notes to the unaudited pro forma condensed combined financial statements.
NOTES TO UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION
The pro forma adjustments have been prepared as if the Business Combination had been consummated on June 30, 2021 in the case of the unaudited pro forma condensed combined balance sheet and on January 1, 2020, the beginning of the earliest period presented in the unaudited pro forma condensed combined statement of operations.
The unaudited pro forma condensed combined financial information has been prepared assuming the following methods of accounting in accordance with GAAP.
The Business Combination is accounted for as a forward recapitalization in accordance with GAAP. Accordingly, for accounting purposes, the financial statements of the combined entity will represent a continuation of the financial statements of Rockley with the acquisition being treated as the equivalent of Rockley issuing stock for the net assets of SC Health, accompanied by a recapitalization. The net assets of SC Health will be stated at historical cost, with no goodwill or other intangible assets recorded.
The pro forma adjustments represent managements estimates based on information available as of the date of this prospectus/proxy statement and are subject to change as additional information becomes available and additional analyses are performed. Management considers this basis of presentation to be reasonable under the circumstances.
One-time direct and incremental transaction costs anticipated to be incurred prior to, or concurrent with, the closing of the Business Combination are reflected in the unaudited pro forma condensed combined balance sheet as a direct reduction to the combined entitys additional paid-in capital (APIC) and are assumed to be cash settled.
The pro forma combined provision for income taxes does not necessarily reflect the amounts that would have resulted had the post-combination company filed consolidated income tax returns during the periods presented.
2. Adjustments and Assumptions to the Unaudited Pro Forma Condensed Combined Balance Sheet as of June 30, 2021.
The unaudited pro forma condensed combined balance sheet as of June 30, 2021 reflects the following adjustments:
Amount | Ref | |||||
(In thousands) | ||||||
Cash inflow from PIPE Financing |
$ | 100,000 | B | |||
Cash inflow from SC Healths trust account |
17,966 | C | ||||
Cash inflow from SC Health Sponsor |
50,000 | D | ||||
Payment from SC Healths deferred IPO fees and SC Healths accrued transaction-related liabilities |
(4,392 | ) | F | |||
Payments of estimated financing fees |
(21,597 | ) | G | |||
Payments of estimated transaction fees incurred by Rockley |
(5,185 | ) | H | |||
Payments of estimated transaction fees incurred by SC Health |
(5,569 | ) | I | |||
Settlement of SC Health promissory note |
(435 | ) | J | |||
|
|
|||||
Net Pro Forma adjustment to cash |
130,788 | A | ||||
|
|
B Represents gross proceeds attributable to the issuance of 10.0 million HoldCo Ordinary Shares for $10 per share, or $100.0 million in aggregate gross proceeds, upon the close of the PIPE Financing that occurred immediately prior to the close of the Business Combination.
C Represents cash equivalents released from SC Healths trust account and relieved of restrictions regarding use upon consummation of the Business Combination and, are available for general use by the combined company.
D Represents gross proceeds attributable to the issuance of 5.0 million shares of HoldCo for $10 per share, or $50 million in gross proceeds from SC Health Sponsor that occurred immediately prior to the close of the Business Combination.
E Represents deferred legal, accounting and other costs incurred as liabilities on Rockleys balance sheet that are directly related to the Transactions. For purposes of the forward recapitalization, these transaction costs are treated as a reduction of the cash proceeds resulting from the Business Combination and accordingly, the deferred asset will be de-recognized as a reduction to additional paid-in capital at the close of the Business Combination. Refer to balance sheet adjustments A for the corresponding adjustments to cash, accounts payable and accrued expenses reported for the combined company and balance sheet adjustment N for the corresponding adjustment to additional paid-in capital reported for the combined company.
F Represents cash used to pay for 1) underwriting fees incurred by SC Health in connection with the Initial Public Offering, for which payment was deferred until consummation of a business combination, and 2) transaction-related expenses accrued and reported as liabilities on SC Healths and Rockleys balance sheet as of June 30, 2021. Detail of amounts accrued on SC Health and Rockleys balance sheets are as follows:
SC Healths deferred IPO underwriting commissions |
$ | 6,038 | ||
Less: IPO underwriting discount |
(1,510 | ) | ||
|
|
|||
SC Healths deferred IPO underwriting commission paid |
4,528 | |||
SC Healths deferred transaction fees |
1,005 | |||
Rockleys deferred transaction fees |
5,201 | |||
|
|
|||
Total deferred costs and accrued expenses paid at or after Business Combination close |
$ | 10,734 | ||
|
|
G Represents financing fees for which payments were made upon consummation of a Business Combination.
H Represents cash that are used or will be used to pay the estimated direct and incremental transaction costs, legal and other fees, that will be due from Rockley on the Business Combination close date, but have not yet been accrued and reported as a liability on Rockleys balance sheet. For purpose of a forward recapitalization transaction, these direct and incremental transaction costs are treated as a reduction of the cash proceeds resulting from the Transactions and, accordingly, reported as a reduction to additional paid-in capital. Refer to balance sheet adjustments N for the corresponding pro forma adjustment to additional paid-in capital reported for the combined company.
I Represents cash used to pay for the estimated direct and incremental transaction costs, legal and other fees, at the consummation of the Business Combination, but have not yet been accrued and reported as a liability on SC Healths balance sheet. For purpose of a forward recapitalization transaction, these direct and incremental transaction costs are treated as a reduction of the cash proceeds resulting from the Transactions and, accordingly, reported as a reduction to additional paid-in capital. Refer to balance sheet adjustments N for the corresponding pro forma adjustment to additional paid-in capital reported for the combined company.
J Represents the current portion of the convertible loan notes that was not converted into equity upon consummation of the business combination.
K Represents SC Health promissory notes payable to related party. The related party forgave $0.6 million of the outstanding balance as of June 30, 2021 and the remaining balance were paid upon the closing of the Business Combination.
L Represents a series of sequential steps of converting most of Rockleys convertible loan notes and related accrued interest to Rockleys ordinary shares at a conversion price of $24.84 per share, then subsequently converting to HoldCos ordinary shares for which HoldCo undertook a stock split prior to the Business Combination. Interest continued to accrue on the convertible notes through the date that the Business Combination consummated, increasing the aggregate notes payable obligation for which HoldCo Ordinary Shares were exchanged. $23.8 million of the convertible loan note did not convert into equity upon consummation of the business combination of which $12.5 million has been reclassified to long-term debt, current portion. Refer to balance sheet adjustment N for the pro forma impact of this exchange on additional paid-in capital reported for the combined company.
M Represents the reclassification of SC Health redeemable Class A ordinary shares to permanent equity upon consummation of Business Combination. Balance sheet adjustment O presents the corresponding pro forma impact that the reclassification of SC Health redeemable Class A ordinary shares to permanent equity would have on the pro forma amounts reported for both the par value of HoldCo ordinary shares and additional paid-in capital of the combined company.
N Represents the net impact of the following pro forma adjustments related to (1) the Business Combination, inclusive of the issuance of HoldCo ordinary shares for Rockleys issued and Outstanding ordinary shares, stock split effected, immediately prior to the Business Combination, SC Healths issued and outstanding Class A ordinary shares prior to the Business Combination, (3) the PIPE Financing, (4) transaction costs, and (5) certain other transactions triggered by the Business Combination on the capital accounts of the combined company:
Holdco
Par Value |
SC Health Par Value |
Rockley
Par Value |
|
|||||||||||||||||
Ordinary
Shares |
Class A
Ordinary Shares |
Class B
Ordinary Shares |
Ordinary
Shares |
Additional
Paid-in Capital |
||||||||||||||||
Redemption of SC Health shares to Class A Ordinary Shares |
| | | | (27,532 | ) | ||||||||||||||
Conversion of SC Health Class B to Class A Ordinary Shares |
| | | | | |||||||||||||||
PIPE Financing |
| | | | 100,000 | |||||||||||||||
SC Health Sponsor |
| | | | 50,000 | |||||||||||||||
Conversion of Rockleys convertible loan notes to Ordinary Shares |
| | | | 170,564 | |||||||||||||||
|
|
|
|
|
|
|
|
|
|
|||||||||||
Adjustment for share issuance and conversion transaction |
| | | | 293,032 | |||||||||||||||
Estimated SC Health transaction costs |
| | | | (4,298 | ) | ||||||||||||||
Estimated Rockleys transaction costs |
| | | | (9,741 | ) | ||||||||||||||
Estimated financing transaction costs |
| | | | (21,597 | ) | ||||||||||||||
Elimination of SC Healths historical retained Earnings |
| | | | (23,402 | ) | ||||||||||||||
|
|
|
|
|
|
|
|
|
|
|||||||||||
Total adjustments to par value and additional paid-in capital |
| | | | 233,994 | |||||||||||||||
|
|
|
|
|
|
|
|
|
|
O Represents the aggregate impact of the pro forma adjustments to the combined companys accumulated deficit to eliminate of SC Health accumulated deficit to additional paid-in capital.
3. Adjustments to the Unaudited Pro Forma Condensed Combined Statement of Operations for the six months ended June 30, 2021 and for the Fiscal year Ended December 31, 2020
The unaudited pro forma condensed combined statement of operations for the six months ended June 30, 2021 and for the fiscal year ended December 31, 2020 reflects the following adjustments:
a Recognition of executive officers and employees compensation under the new employment agreements for the period after Business Combination. The adjustment does not include $3.8 million in bonuses to our executive officers and employees that will be paid contingent upon, and no later than shortly following, the closing of the Business Combination because these bonuses will not have a continuing impact on ongoing operations.
b Recognition of executive officers and employees stock compensation for the period after Business Combination.
c Recognition of Director Compensation Program RSU and Cash Considerations for the period prior to the 2021 Business Combination.
d Represents the elimination of interest income earned on cash equivalents held in SC Healths trust account during the period. Cash equivalents will be released from SC Healths trust account and available for general use by the combined company at the consummation of the Business Combination.
e Represents the elimination of the Forward Purchase Agreement with SC Health at the consummation of the Business Combination.
f Basic and diluted net loss per share as a result of the pro forma adjustments.
g Basic and diluted weighted average ordinary shares outstanding as a result of the pro forma adjustments.
h Represents the elimination of adjustments to the fair value of convertible loan notes which were converted into Rockleys Ordinary shares prior to closing of the Business Combination.
Six Months Ended | Year Ended | |||||||
June 30, 2021 | December 31, 2020 | |||||||
Numerator |
||||||||
Pro forma net loss |
$ | (66,725 | ) | $ | (69,222 | ) | ||
Denominator |
||||||||
Current Rockley Shareholders |
103,916,607 | 103,916,607 | ||||||
SC Health Shareholders |
1,777,150 | 1,777,150 | ||||||
Sponsor Shareholders |
10,562,500 | 10,562,500 | ||||||
PIPE Investors |
10,000,000 | 10,000,000 | ||||||
|
|
|
|
|||||
Total |
126,256,257 | 126,256,257 | ||||||
Net loss per share |
||||||||
Basic and diluted |
$ | (0.53 | ) | $ | (0.55 | ) |
Exhibit 99.2
Part I. Financial Information
Item 1. Financial Statements
SC HEALTH CORPORATION
CONDENSED BALANCE SHEETS
June 30,
2021 |
December 31,
2020 |
|||||||
(Unaudited) | ||||||||
ASSETS |
||||||||
Current Assets |
||||||||
Cash |
$ | 35,244 | $ | 124,878 | ||||
Prepaid expenses |
47,876 | 122,067 | ||||||
|
|
|
|
|||||
Total Current Assets |
83,120 | 246,945 | ||||||
Marketable securities held in Trust Account |
93,838,960 | 174,542,012 | ||||||
|
|
|
|
|||||
TOTAL ASSETS |
$ | 93,922,080 | $ | 174,788,957 | ||||
|
|
|
|
|||||
LIABILITIES AND SHAREHOLDERS EQUITY |
||||||||
Current liabilities |
||||||||
Account payable and accrued expenses |
$ | 1,004,661 | $ | 1,037,048 | ||||
Accrued offering costs |
167 | 167 | ||||||
Promissory note related party |
1,035,000 | 100,000 | ||||||
|
|
|
|
|||||
Total Current Liabilities |
2,039,828 | 1,137,215 | ||||||
Warrant liabilities |
32,502,932 | 19,055,750 | ||||||
Forward purchase agreement liabilities |
| 2,950,567 | ||||||
Deferred underwriting fee payable |
6,037,500 | 6,037,500 | ||||||
|
|
|
|
|||||
Total Liabilities |
40,580,260 | 29,181,032 | ||||||
Commitments and Contingencies (Note 5) |
||||||||
Class A ordinary shares subject to possible redemption, 4,834,181 and 14,060,762 shares at $10.00 per share as of June 30, 2021 and December 31, 2020, respectively |
48,341,810 | 140,607,920 | ||||||
Shareholders Equity |
||||||||
Preference shares, $0.0001 par value; 1,000,000 shares authorized; none issued and outstanding |
| | ||||||
Class A ordinary shares, $0.0001 par value; 180,000,000 shares authorized; 4,440,334 and 3,189,208 shares issued and outstanding (excluding 4,834,181 and 14,060,762 shares subject to possible redemption) as of June 30, 2021 and December 31, 2020, respectively |
444 | 319 | ||||||
Class B ordinary shares, $0.00008 par value; 25,000,000 shares authorized; 5,562,500 shares issued and outstanding as of June 30, 2021 and December 31, 2020 |
445 | 445 | ||||||
Additional paid-in capital |
30,381,594 | 18,827,517 | ||||||
Accumulated deficit |
(25,382,473 | ) | (13,828,276 | ) | ||||
|
|
|
|
|||||
Total Shareholders Equity |
5,000,010 | 5,000,005 | ||||||
|
|
|
|
|||||
TOTAL LIABILITIES AND SHAREHOLDERS EQUITY |
$ | 93,922,080 | $ | 174,788,957 | ||||
|
|
|
|
The accompanying notes are an integral part of these unaudited condensed interim financial statements.
SC HEALTH CORPORATION
CONDENSED INTERIM STATEMENTS OF OPERATIONS
(Unaudited)
Three Months
Ended June 30, |
Six Months
Ended June 30, |
|||||||||||||||
2021 | 2020 | 2021 | 2020 | |||||||||||||
General and operating expenses |
$ | 801,896 | $ | 136,354 | $ | 1,066,438 | $ | 348,637 | ||||||||
|
|
|
|
|
|
|
|
|||||||||
Loss from operations |
(801,896 | )) | (136,354 | )) | (1,066,438 | )) | (348,637 | )) | ||||||||
Other income (expense): |
||||||||||||||||
Interest earned on investments held in Trust Account |
3,376 | 70,520 | 8,856 | 628,159 | ||||||||||||
Change in fair value of warrant liabilities |
798,410 | (1,743,500 | )) | (13,447,182 | )) | (1,689,000 | )) | |||||||||
Change in fair value of forward purchase agreement |
| (451,927 | )) | 2,950,567 | (612,025 | )) | ||||||||||
|
|
|
|
|
|
|
|
|||||||||
Other income (expense), net |
801,786 | (2,124,907 | )) | (10,487,759 | )) | (1,672,866 | )) | |||||||||
Net loss |
$ | (110 | )) | $ | (2,261,261 | )) | $ | (11,554,197 | )) | $ | (2,021,503 | )) | ||||
|
|
|
|
|
|
|
|
|||||||||
Weighted average shares outstanding of Class A redeemable ordinary shares |
10,501,513 | 17,250,000 | 13,857,114 | 17,250,000 | ||||||||||||
|
|
|
|
|
|
|
|
|||||||||
Basic and diluted net income per share, Class A |
$ | 0.00 | $ | 0.00 | $ | 0.00 | $ | 0.04 | ||||||||
|
|
|
|
|
|
|
|
|||||||||
Weighted average shares outstanding of Class B non-redeemable ordinary shares |
5,562,500 | 5,562,500 | 5,562,500 | 5,562,500 | ||||||||||||
|
|
|
|
|
|
|
|
|||||||||
Basic and diluted net loss per share, Class B |
$ | (0.00 | ) | $ | (0.42 | )) | $ | (2.08 | )) | $ | (0.48 | )) | ||||
|
|
|
|
|
|
|
|
The accompanying notes are an integral part of these unaudited condensed interim financial statements.
2
SC HEALTH CORPORATION
CONDENSED STATEMENTS OF CHANGES IN SHAREHOLDERS EQUITY
(Unaudited)
THREE AND SIX MONTHS ENDED JUNE 30, 2021
Class A
Ordinary Shares |
Class B
Ordinary Shares |
Additional
Paid-in Capital |
Accumulated
Deficit |
Total
Shareholders Equity |
||||||||||||||||||||||||
Shares | Amount | Shares | Amount | |||||||||||||||||||||||||
Balance January 1, 2021 |
3,189,208 | $ | 319 | 5,562,500 | $ | 445 | $ | 18,827,517 | $ | (13,828,276 | ) | $ | 5,000,005 | |||||||||||||||
Change in value of ordinary shares subject to possible redemption |
(1,155,409 | ) | 115 | | | 11,553,974 | | 11,554,089 | ||||||||||||||||||||
Net loss |
| | | | | (11,554,087 | ) | (11,554,087 | ) | |||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||
Balance March 31, 2021 (unaudited) |
4,344,617 | $ | 434 | 5,562,500 | $ | 445 | $ | 30,381,491 | $ | (25,382,363 | ) | $ | 5,000,007 | |||||||||||||||
Change in value of ordinary shares subject to possible redemption(1) |
95,717 | 10 | | | 103 | | 113 | |||||||||||||||||||||
Net income |
| | | | | (110 | ) | (110 | ) | |||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||
Balance June 30, 2021 (unaudited) |
4,440,334 | $ | 444 | 5,562,500 | $ | 445 | $ | 30,381,594 | $ | (25,382,473 | ) | $ | 5,000,010 | |||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
3
THREE AND SIX MONTHS ENDED JUNE 30, 2020
Class A
Ordinary Shares |
Class B
Ordinary Shares |
Additional
Paid in Capital |
Accumulated
Deficit |
Total
Shareholders Equity |
||||||||||||||||||||||||
Shares | Amount | Shares | Amount | |||||||||||||||||||||||||
Balance January 1, 2020 |
2,366,966 | $ | 237 | 5,562,500 | $ | 445 | $ | 10,605,179 | $ | (5,605,856 | ) | $ | 5,000,005 | |||||||||||||||
Change in value of ordinary shares subject to possible redemption |
(23,976 | ) | (3 | ) | | | (239,757 | ) | | (239,760 | ) | |||||||||||||||||
Net income |
| | | | | 239,758 | 239,758 | |||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||
Balance March 31, 2020 (unaudited) |
2,342,990 | $ | 234 | 5,562,500 | $ | 445 | $ | 10,365,422 | $ | (5,366,098 | ) | $ | 5,000,003 | |||||||||||||||
Change in value of ordinary shares subject to possible redemption |
226,126 | 23 | | | 2,261,237 | | 2,261,260 | |||||||||||||||||||||
Net loss |
| | | | | (2,261,261 | ) | (2,261,261 | ) | |||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||
Balance June 30, 2020 (unaudited) |
2,569,116 | $ | 257 | 5,562,500 | $ | 445 | $ | 12,626,659 | $ | (7,627,359 | ) | $ | 5,000,002 | |||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(1) |
Includes the effect of the redemption of Class A ordinary shares on April 16, 2021. Shareholders holding 7,975,485 shares exercised their right to convert such shares into a pro-rata portion of the Trust Account (see Note 1). |
The accompanying notes are an integral part of these unaudited condensed interim financial statements.
4
SC HEALTH CORPORATION
CONDENSED STATEMENTS OF CASH FLOWS
(Unaudited)
Six Months Ended
June 30, |
||||||||
2021 | 2020 | |||||||
Cash Flows from Operating Activities: |
||||||||
Net loss |
$ | (11,554,197 | ) | $ | (2,021,503 | ) | ||
Adjustments to reconcile net loss to net cash used in operating activities: |
||||||||
Change in fair value of warrant liabilities |
13,447,182 | 1,689,000 | ||||||
Change in fair value of FPA liability |
(2,950,567 | ) | 612,025 | |||||
Interest earned on marketable securities held in Trust Account |
(8,856 | ) | (628,159 | ) | ||||
Changes in operating assets and liabilities: |
||||||||
Prepaid expenses |
74,191 | 70,350 | ||||||
Accounts payable and accrued expenses |
(32,387 | ) | (36,509 | ) | ||||
|
|
|
|
|||||
Net cash used in operating activities |
(1,024,634 | ) | (314,796 | ) | ||||
|
|
|
|
|||||
Cash Flows from Investing Activities: |
||||||||
Cash withdrawn from Trust account for redemptions |
80,711,908 | | ||||||
|
|
|
|
|||||
Net cash provided by investing activities |
80,711,908 | | ||||||
|
|
|
|
|||||
Cash Flows from Financing Activities: |
||||||||
Proceeds from promissory note/advances related party |
935,000 | | ||||||
Redemption of Class A ordinary shares |
(80,711,908 | ) | | |||||
|
|
|
|
|||||
Net cash used in financing activities |
(79,776,908 | ) | | |||||
|
|
|
|
|||||
Net Change in Cash |
(89,634 | ) | (314,796 | ) | ||||
Cash Beginning |
124,878 | 772,413 | ||||||
|
|
|
|
|||||
Cash Ending |
$ | 35,244 | $ | 457,617 | ||||
|
|
|
|
|||||
Non-Cash Investing and Financing Activities: |
||||||||
Change in value of Class A ordinary shares subject to possible redemption |
$ | (11,554,202 | ) | $ | (2,021,500 | ) | ||
|
|
|
|
The accompanying notes are an integral part of these unaudited condensed interim financial statements.
5
SC HEALTH CORPORATION
NOTES TO CONDENSED INTERIM FINANCIAL STATEMENTS
JUNE 30, 2021
(Unaudited)
Note 1 Description of Organization and Business Operations
SC Health Corporation (the Company) is a blank check company incorporated in the Cayman Islands on December 10, 2018. The Company was formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, recapitalization or similar business combination with one or more businesses (the Business Combination).
Although the Company is not limited to a particular industry or geographic region for purposes of consummating a Business Combination, the Company is focusing its search on companies with operations or prospects in the healthcare sector in the Asia Pacific region. The Company is an early stage and emerging growth company and, as such, the Company is subject to all of the risks associated with early stage and emerging growth companies.
As of June 30, 2021, the Company had not commenced any operations. All activity through June 30, 2021 relates to the Companys formation, the initial public offering (Initial Public Offering), which is described below, and, after the Initial Public Offering, identifying a target company for a Business Combination. The Company will not generate any operating revenues until after the completion of its initial Business Combination, at the earliest. The Company generates non-operating income in the form of interest income from the proceeds derived from the Initial Public Offering.
The registration statement for the Companys Initial Public Offering was declared effective on July 11, 2019. On July 16, 2019, the Company consummated the Initial Public Offering of 15,000,000 units (the Units and, with respect to the shares of Class A ordinary shares included in the Units sold, the Public Shares), which is described in Note 3.
Simultaneously with the closing of the Initial Public Offering, the Company consummated the sale of 5,000,000 warrants (the Private Placement Warrants) at a price of $1.00 per Private Placement Warrant in a private placement to SC Health Holdings Limited, a Cayman Islands exempted company (the Sponsor), generating gross proceeds of $5,000,000, which is described in Note 4.
Following the closing of the Initial Public Offering on July 16, 2019, an amount of $150,000,000 ($10.00 per Unit) from the net proceeds of the sale of the Units in the Initial Public Offering and the sale of the Private Placement Warrants was placed in a trust account (the Trust Account) and invested in U.S. government securities, within the meaning set forth in Section 2(a)(16) of the Investment Company Act, with a maturity of 180 days or less or in any open-ended investment company that holds itself out as a money market fund selected by the Company meeting the conditions of Rule 2a-7 of the Investment Company Act of 1940, as amended (the Investment Company Act), as determined by the Company, until the earlier of: (i) the completion of a Business Combination and (ii) the distribution of the Trust Account, as described below.
On August 2, 2019, in connection with the underwriters election to fully exercise their over-allotment option, the Company consummated the sale of an additional 2,250,000 Units at $10.00 per Unit and the sale of an additional 450,000 Private Placement Warrants at $1.00 per Private Placement Warrant, generating total gross proceeds of $22,950,000. Following the closing, an additional $22,500,000 of net proceeds was placed in the Trust Account, resulting in $172,500,000 held in the Trust Account.
Transaction costs amounted to $10,224,407, consisting of $3,450,000 of underwriting fees, $6,037,500 of deferred underwriting fees and $736,907 of other offering costs.
Substantially all of the net proceeds of the Initial Public Offering and the sale of the Private Placement Warrants are intended to be applied toward consummating a Business Combination, and the Companys management has broad discretion to identify targets for such a potential Business Combination and over the specific application of the funds held in the Trust Account if and when such funds are properly released from the Trust Account. The Companys initial Business Combination must be with one or more target businesses that together have a fair market value of at least 80% of the net assets held in the Trust Account (net of amounts disbursed to management for working capital purposes and excluding deferred underwriting discount) at the time of the agreement to enter into a Business Combination. The Company will only complete a Business Combination if the post-transaction company owns or acquires 50% or more of the outstanding voting securities of the target or otherwise acquires a controlling interest in the target sufficient for it not to be required to register as an investment company under the Investment Company Act. There is no assurance that the Company will be able to complete a Business Combination successfully.
6
The Company will provide its holders of the outstanding Public Shares (the public shareholders) with the opportunity to redeem all or a portion of their Public Shares upon the completion of a Business Combination either (i) in connection with a shareholder meeting called to approve the Business Combination or (ii) by means of a tender offer. The decision as to whether the Company will seek shareholder approval of a Business Combination or conduct a tender offer will be made by the Company, solely in its discretion. The public shareholders will be entitled to redeem their Public Shares for a pro rata portion of the amount then in the Trust Account ($10.00 per Public Share, plus any pro rata interest earned on the funds held in the Trust Account and not previously released to the Company to pay its tax obligations). The per-share amount to be distributed to public shareholders who redeem their Public Shares will not be reduced by the deferred underwriting commissions the Company will pay to the underwriters (as discussed in Note 5). There will be no redemption rights upon the completion of a Business Combination with respect to the Companys warrants.
The Company will proceed with a Business Combination only if the Company has net tangible assets of at least $5,000,001 upon such consummation of a Business Combination and, if the Company seeks shareholder approval, a majority of the shares voted are voted in favor of the Business Combination. If a shareholder vote is not required by law and the Company does not decide to hold a shareholder vote for business or other legal reasons, the Company will, pursuant to its amended and restated memorandum and articles of association (Memorandum and Articles of Association), conduct the redemptions pursuant to the tender offer rules of the U.S. Securities and Exchange Commission (SEC) and file tender offer documents with the SEC prior to completing a Business Combination. If, however, shareholder approval of the transactions is required by law, or the Company decides to obtain shareholder approval for business or legal reasons, the Company will offer to redeem shares in conjunction with a proxy solicitation pursuant to the proxy rules and not pursuant to the tender offer rules. Additionally, each public shareholder may elect to redeem their Public Shares irrespective of whether they vote for or against the proposed transaction. If the Company seeks shareholder approval in connection with a Business Combination, the Sponsor, executive officers and directors (the initial shareholders) have agreed to vote their Founder Shares (as defined in Note 4) and any Public Shares purchased during or after the Initial Public Offering in favor of approving a Business Combination.
Notwithstanding the foregoing, if the Company seeks shareholder approval of a Business Combination and it does not conduct redemptions pursuant to the tender offer rules, the Memorandum and Articles of Association provides that a public shareholder, together with any affiliate of such shareholder or any other person with whom such shareholder is acting in concert or as a group (as defined under Section 13 of the Securities Exchange Act of 1934, as amended (the Exchange Act)), will be restricted from redeeming its shares with respect to more than an aggregate of 20% or more of the Public Shares, without the prior consent of the Company.
The initial shareholders have agreed (a) to waive their redemption rights with respect to their Founder Shares and Public Shares held by them in connection with the completion of a Business Combination and (b) not to propose an amendment to the Memorandum and Articles of Association to modify the substance or timing of the Companys obligation to redeem 100% of its Public Shares if the Company does not complete a Business Combination, unless the Company provides the public shareholders with the opportunity to redeem their Public Shares in conjunction with any such amendment.
The Company initially had until January 16, 2021, or such later date as a result of a shareholder vote to amend the Memorandum and Articles of Association, to complete a Business Combination (the Combination Period). If the Company is unable to complete a Business Combination within the Combination Period, the Company will (i) cease all operations except for the purpose of winding up, (ii) as promptly as reasonably possible but not more than ten business days thereafter, redeem the Public Shares, at a per-share price, payable in cash, equal to the aggregate amount then on deposit in the Trust Account including interest earned on the funds held in the Trust Account and not previously released to the Company to pay its tax obligations (less up to $100,000 of interest to pay dissolution expenses), divided by the number of then outstanding Public Shares, which redemption will completely extinguish public shareholders rights as shareholders (including the right to receive further liquidating distributions, if any), subject to applicable law, and (iii) as promptly as reasonably possible following such redemption, subject to the approval of the Companys remaining shareholders and the Companys board of directors, dissolve and liquidate, subject in each case to the Companys obligations under Cayman Islands law to provide for claims of creditors and the requirements of other applicable law. There will be no redemption rights or liquidating distributions with respect to the Companys warrants, which will expire worthless if the Company fails to complete a Business Combination within the Combination Period.
On January 12, 2021, the Company held an extraordinary general meeting pursuant to which the Companys shareholders approved extending the Combination Period from January 16, 2021 to April 16, 2021. In connection with the approval of the extension, no shareholders elected to redeem their shares for cash. On April 14, 2021, the Company held an extraordinary general meeting pursuant to which the Companys shareholders approved extending the Combination Period from April 16, 2021 to August 16, 2021 (the Extension Date). In connection with the approval of the extension, shareholders elected to redeem 7,975,485 of Class A ordinary shares for cash amounting $80,711,908.
7
The initial shareholders have agreed to waive their liquidation rights with respect to the Founder Shares if the Company fails to complete a Business Combination within the Combination Period. However, if the initial shareholders acquire Public Shares in or after the Initial Public Offering, such Public Shares will be entitled to liquidating distributions from the Trust Account if the Company fails to complete a Business Combination within the Combination Period. The underwriters have agreed to waive their rights to their deferred underwriting commission (see Note 5) held in the Trust Account in the event the Company does not complete a Business Combination within the Combination Period and, in such event, such amounts will be included with the other funds held in the Trust Account that will be available to fund the redemption of the Public Shares. In the event of such distribution, it is possible that the per share value of the assets remaining available for distribution will be less than the Initial Public Offering price per Unit ($10.00).
In order to protect the amounts held in the Trust Account, the Sponsor has agreed to be liable to the Company if and to the extent any claims by a vendor for services rendered or products sold to the Company, or a prospective target business with which the Company has discussed entering into a transaction agreement, reduce the amounts in the Trust Account to below the lesser of (i) $10.00 per share and (ii) the actual amount per Public Share held in the Trust Account if less than $10.00 per Public Share due to reductions in the value of the trust assets. This liability will not apply with respect to any claims by a third party who executed a waiver of any and all rights to seek access to the Trust Account nor to any claims under the Companys indemnity of the underwriters of the Initial Public Offering against certain liabilities, including liabilities under the Securities Act of 1933, as amended (the Securities Act). Moreover, in the event that an executed waiver is deemed to be unenforceable against a third party, the Sponsor will not be responsible to the extent of any liability for such third-party claims. The Company will seek to reduce the possibility that the Sponsor will have to indemnify the Trust Account due to claims of creditors by endeavoring to have all vendors, service providers (except for the Companys independent auditors), prospective target businesses or other entities with which the Company does business, execute agreements with the Company waiving any right, title, interest or claim of any kind in or to monies held in the Trust Account.
Going Concern
In connection with the Companys assessment of going concern considerations in accordance with Financial Accounting Standard Boards Accounting Standards Update (ASU) 2014-15, Disclosures of Uncertainties about an Entitys Ability to Continue as a Going Concern, the Company has until August 16, 2021, to consummate the proposed Business Combination. It is uncertain that the Company will be able to consummate the proposed Business Combination by this time. Additionally, the Company may not have sufficient liquidity to fund the working capital needs of the Company through one year from the issuance of these financial statements. If a business combination is not consummated by this date, there will be a mandatory liquidation and subsequent dissolution of the Company. Management has determined that the liquidity condition and mandatory liquidation, should a business combination not occur, and potential subsequent dissolution, raises substantial doubt about the Companys ability to continue as a going concern. No adjustments have been made to the carrying amounts of assets or liabilities should the Company be required to liquidate after August 16, 2021. The Company intends to complete the proposed Business Combination before the mandatory liquidation date. However, there can be no assurance that the Company will be able to consummate any business combination by August 16, 2021.
Note 2 Summary of Significant Accounting Policies
Basis of Presentation
The accompanying unaudited condensed interim financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (GAAP) for interim financial information and in accordance with the instructions to Form 10-Q and Article 8 of Regulation S-X of the SEC. Certain information or footnote disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted, pursuant to the rules and regulations of the SEC for interim financial reporting. Accordingly, they do not include all the information and footnotes necessary for a complete presentation of financial position, results of operations, or cash flows. In the opinion of management, the accompanying unaudited condensed interim financial statements include all adjustments, consisting of a normal recurring nature, which are necessary for a fair presentation of the financial position, operating results and cash flows for the periods presented.
The accompanying unaudited condensed interim financial statements should be read in conjunction with the Companys Annual Report on Form 10-K/A for the year ended December 31, 2020 as filed with the SEC on May 26, 2021, which contains the audited financial statements and notes thereto. The interim results for the three and six months ended June 30, 2021 are not necessarily indicative of the results to be expected for the year ending December 31, 2021 or for any future interim periods.
8
Emerging Growth Company
The Company is an emerging growth company, as defined in Section 2(a) of the Securities Act, as modified by the Jumpstart Our Business Startups Act of 2012 (the JOBS Act), and it may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies including, but not limited to, not being required to comply with the independent registered public accounting firm attestation requirements of Section 404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in its periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and shareholder approval of any golden parachute payments not previously approved.
Further, Section 102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the Exchange Act) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that a company can elect to opt out of the extended transition period and comply with the requirements that apply to non-emerging growth companies but any such election to opt out is irrevocable. The Company has elected not to opt out of such extended transition period which means that when a standard is issued or revised and it has different application dates for public or private companies, the Company, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard. This may make comparison of the Companys financial statement with another public company which is neither an emerging growth company nor an emerging growth company which has opted out of using the extended transition period difficult or impossible because of the potential differences in accounting standards used.
The Company will remain an emerging growth company until the earlier of (1) the last day of the fiscal year (a) following the fifth anniversary of the completion of its Initial Public Offering, (b) in which the Company has total annual gross revenue of at least $1.07 billion, or (c) in which the Company is deemed to be a large accelerated filer, which means the market value of its ordinary shares that is held by non-affiliates exceeds $700 million as of the prior June 30th, and (2) the date on which the Company has issued more than $1.0 billion in non-convertible debt securities during the prior three-year period. References herein to emerging growth company shall have the meaning associated with it in the JOBS Act.
Use of Estimates
The preparation of the unaudited condensed interim financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the unaudited condensed interim financial statements and the reported amounts of expenses during the reporting periods.
Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the financial statements, which management considered in formulating its estimate, could change in the near term due to one or more future confirming events. One of the more significant accounting estimates included in these financial statements is the determination of the fair value of the warrant liability. Such estimates may be subject to change as more current information becomes available and, accordingly, the actual results could differ significantly from those estimates.
Investments Held in Trust Account
As of June 30, 2021 and December 31, 2020, assets held in the Trust Account were invested in Money Market Funds.
Class A Ordinary Shares Subject to Possible Redemption
The Company accounts for its Class A ordinary shares subject to possible redemption in accordance with the guidance in ASC Topic 480 Distinguishing Liabilities from Equity. Class A ordinary shares subject to mandatory redemption are classified as a liability instrument and are measured at fair value. Conditionally redeemable ordinary shares (including ordinary shares that features redemption rights that is either within the control of the holder or subject to redemption upon the occurrence of uncertain events not solely within the Companys control) are classified as temporary equity. At all other times, ordinary shares are classified as shareholders equity. The Companys Class A ordinary shares feature certain redemption rights that are considered to be outside of the Companys control and subject to occurrence of uncertain future events. Accordingly, at June 30, 2021 and December 31, 2020, Class A ordinary shares subject to possible redemption is presented as temporary equity, outside of the shareholders equity section of the Companys condensed balance sheets.
9
Offering Costs
Offering costs consisted of legal, accounting and other expenses incurred through the Initial Public Offering that were directly related to the Initial Public Offering. Offering costs were allocated to the separable financial instruments issued in the Initial Public Offering based on a relative fair value basis, compared to total proceeds received. Offering costs allocated to warrant liabilities were expensed as incurred in the statements of operations. Offering costs associated with the Class A ordinary shares issued were charged to shareholders equity upon the completion of the Initial Public Offering.
Warrant Liabilities
The Company does not use derivative instruments to hedge exposures to cash flow, market, or foreign currency risks. The Company evaluates all of its financial instruments, including issued stock purchase warrants, to determine if such instruments are derivatives or contain features that qualify as embedded derivatives, pursuant to ASC 480 and FASB ASC Topic 815, Derivatives and Hedging (ASC 815).Company accounts for the Warrants as either equity-classified or liability-classified instruments based on an assessment of the specific terms of the Warrants and applicable authoritative guidance in Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) 480, Distinguishing Liabilities from Equity (ASC 480) and ASC 815, Derivatives and Hedging (ASC 815). The assessment considers whether the Warrants and are freestanding financial instruments pursuant to ASC 480, meet the definition of a liability pursuant to ASC 480, and meet all of the requirements for equity classification under ASC 815, including whether the Warrants and are indexed to the Companys own ordinary shares and whether the holders of the Warrants could potentially require net cash settlement in a circumstance outside of the Companys control, among other conditions for equity classification. This assessment, which requires the use of professional judgment, is conducted at the time of issuance of the Warrants as of each subsequent quarterly period end date while the Warrants are outstanding. For issued or modified warrants that meet all of the criteria for equity classification, such warrants are required to be recorded as a component of additional paid-in capital at the time of issuance. For issued or modified warrants that do not meet all the criteria for equity classification, liability-classified warrants are required to be recorded at their initial fair value on the date of issuance, and each balance sheet date thereafter. Changes in the estimated fair value of such warrants are recognized as a non-cash gain or loss on the statements of operations.
The Company accounts for the Warrants in accordance with ASC 815-40 under which the Warrants do not meet the criteria for equity classification and must be recorded as liabilities. The fair value of the Public Warrants was initially estimated using a Monte Carlo simulation model with subsequent measurements estimated using the Public Warrants quoted market price. The Private Placement Warrants are valued using a Modified Black Scholes Option Pricing Model.
Income Taxes
The Company accounts for income taxes under ASC Topic 740, Income Taxes, which prescribes a recognition threshold and a measurement attribute for the financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more-likely-than-not to be sustained upon examination by taxing authorities. The Companys management determined that the Cayman Islands is the Companys major tax jurisdiction. The Company recognizes accrued interest and penalties related to unrecognized tax benefits as income tax expense. As of June 30, 2021 and December 31, 2020, there were no unrecognized tax benefits and no amounts accrued for interest and penalties. The Company is currently not aware of any issues under review that could result in significant payments, accruals or material deviation from its position.
The Company is considered to be an exempted Cayman Islands company with no connection to any other taxable jurisdiction and is presently not subject to income taxes or income tax filing requirements in the Cayman Islands or the United States. As such, the Companys tax provision was zero for the periods presented. The Companys management does not expect that the total amount of unrecognized tax benefits will materially change over the next twelve months.
Net Income (Loss) per Ordinary Share
Net income (loss) per ordinary share is computed by dividing net income (loss) by the weighted average number of ordinary shares outstanding for the period. The calculation of diluted income (loss) per ordinary share does not consider the effect of the warrants issued in connection with the (i) Initial Public Offering, (ii) the exercise of the over-allotment option and (iii) Private Placement Warrants since the exercise of the warrants are contingent upon the occurrence of future events and the inclusion of such warrants would be anti-dilutive. The warrants are exercisable to purchase 14,075,000 shares of Class A ordinary shares in the aggregate.
10
The Companys condensed statements of operations include a presentation of income (loss) per share for ordinary shares subject to possible redemption in a manner similar to the two-class method of income (loss) per share. Net income per share, basic and diluted, for Class A redeemable ordinary shares is calculated by dividing the interest income earned on the Trust Account, by the weighted average number of Class A redeemable ordinary shares outstanding since original issuance. Net loss per share, basic and diluted, for Class B non-redeemable ordinary shares is calculated by dividing the net loss, adjusted for income attributable to Class A redeemable ordinary shares, by the weighted average number of Class B non-redeemable ordinary shares outstanding for the period. Class B non-redeemable ordinary shares includes the Founder Shares as these shares do not have any redemption features and do not participate in the income earned on the Trust Account.
The following table reflects the calculation of basic and diluted net income (loss) per ordinary share (in dollars, except per share amounts):
Three Months
Ended June 30, |
Six Months
Ended June 30, |
|||||||||||||||
2021 | 2020 | 2021 | 2020 | |||||||||||||
Redeemable Class A Ordinary Shares |
||||||||||||||||
Numerator: Earnings allocable to Redeemable Class A Ordinary Shares |
||||||||||||||||
Interest Income |
$ | 3,376 | $ | 70,520 | $ | 8,856 | $ | 628,159 | ||||||||
|
|
|
|
|
|
|
|
|||||||||
Redeemable Net Earnings |
$ | 3,376 | $ | 70,520 | $ | 8,856 | $ | 628,159 | ||||||||
|
|
|
|
|
|
|
|
|||||||||
Denominator: Weighted Average Redeemable Class A Ordinary Shares |
||||||||||||||||
Redeemable Class A Ordinary Shares, Basic and Diluted |
10,501,513 | 17,250,000 | 13,857,114 | 17,250,000 | ||||||||||||
Earnings/Basic and Diluted Redeemable Class A Ordinary Shares |
$ | 0.00 | $ | 0.00 | $ | 0.00 | $ | 0.04 | ||||||||
|
|
|
|
|
|
|
|
|||||||||
Non-Redeemable Class B Ordinary Shares |
||||||||||||||||
Numerator: Net Income (Loss) minus Redeemable Net Earnings |
||||||||||||||||
Net Income (Loss) |
$ | (110 | ) | $ | (2,261,261 | ) | $ | (11,554,197 | ) | $ | (2,021,503 | ) | ||||
Less: Redeemable Net Earnings |
(3,376 | ) | (70,520 | ) | (8,856 | ) | (628,159 | ) | ||||||||
|
|
|
|
|
|
|
|
|||||||||
Non-Redeemable Net Income (Loss) |
$ | (3,486 | ) | $ | (2,331,781 | ) | $ | (11,563,053 | ) | $ | (2,649,662 | ) | ||||
|
|
|
|
|
|
|
|
|||||||||
Denominator: Weighted Average Non-Redeemable Class B Ordinary Shares |
||||||||||||||||
Non-Redeemable Class B Ordinary Shares, Basic and Diluted |
5,562,500 | 5,562,500 | 5,562,500 | 5,562,500 | ||||||||||||
Loss/Basic and Diluted Non-Redeemable Class B Ordinary Shares |
$ | 0.00 | $ | (0.42 | ) | $ | (2.08 | ) | $ | (0.48 | ) | |||||
|
|
|
|
|
|
|
|
Concentration of Credit Risk
Financial instruments that potentially subject the Company to concentrations of credit risk consist of a cash account in a financial institution, which, at times, may exceed the Federal Depository Insurance Corporation coverage of $250,000. The Company has not experienced losses on this account and management believes the Company is not exposed to significant risks on such account.
Fair Value of Financial Instruments
The fair value of the Companys assets and liabilities which qualify as financial instruments under ASC Topic 820, Fair Value Measurement, approximate the carrying amounts represented in the accompanying condensed balance sheets, primarily due to their short-term nature other than the warrant liabilities (see Note 8).
11
Fair Value Measurements
Fair value is defined as the price that would be received for sale of an asset or paid for transfer of a liability, in an orderly transaction between market participants at the measurement date. GAAP establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). These tiers include:
|
Level 1, defined as observable inputs such as quoted prices (unadjusted) for identical instruments in active markets; |
|
Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable such as uoted prices for similar instruments in active markets or quoted prices for identical or similar instruments in markets that are not active; and |
|
Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions, such as valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable. |
In some circumstances, the inputs used to measure fair value might be categorized within different levels of the fair value hierarchy. In those instances, the fair value measurement is categorized in its entirety in the fair value hierarchy based on the lowest level input that is significant to the fair value measurement.
Derivative Financial Instruments
The Company evaluates its financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded derivatives in accordance with ASC Topic 815, Derivatives and Hedging. For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its fair value on the grant date and is then re-valued at each reporting date, with changes in the fair value reported in the statements of operations. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is evaluated at the end of each reporting period. Derivative liabilities are classified in the balance sheet as current or non-current based on whether or not net-cash settlement or conversion of the instrument could be required within 12 months of the balance sheet date.
Recent Accounting Standards
In August 2020, the FASB issued ASU No. 2020-06, DebtDebt with Conversion and Other Options (Subtopic 470-20) and Derivatives and HedgingContracts in Entitys Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entitys Own Equity (ASU 2020-06), which simplifies accounting for convertible instruments by removing major separation models required under current GAAP. ASU 2020-06 removes certain settlement conditions that are required for equity contracts to qualify for the derivative scope exception and it also simplifies the diluted earnings per share calculation in certain areas. ASU 2020-06 is effective for fiscal years beginning after December 15, 2023, including interim periods within those fiscal years, with early adoption permitted. The Company is currently assessing the impact, if any, that ASU 2020-06 would have on its financial position, results of operations or cash flows.
Management does not believe that any other recently issued, but not yet effective, accounting standards, if currently adopted, would have a material effect on the Companys unaudited condensed interim financial statements.
Note 3 Public Offering
Pursuant to the Initial Public Offering, the Company sold 17,250,000 Units at a purchase price of $10.00 per Unit, inclusive of 2,250,000 Units sold to the underwriters on August 2, 2019 upon the underwriters election to fully exercise their over-allotment option. Each Unit consists of one Class A ordinary share and one-half of one redeemable warrant (Public Warrant). Each whole Public Warrant entitles the holder to purchase one Class A ordinary share at a price of $11.50 per share, subject to adjustment (see Note 7).
12
Note 4 Related Party Transactions
Founder Shares
In December 2018, the Sponsor purchased 3,450,000 shares (the Founder Shares) of the Companys Class B ordinary shares for an aggregate price of $25,000. On February 8, 2019, the Company completed a sub-division of its Class B ordinary shares, pursuant to which the Founder Shares were sub-divided into 4,312,500 shares with a par value of $0.00008 per share. All share and per-share amounts have been retroactively restated to reflect the sub-division. On July 9, 2019, the Company issued 1,250,000 Founder Shares to the Sponsor in connection with the forward purchase agreement (see Note 5) for par value, or $100, resulting in a total of 5,562,500 Founder Shares issued and outstanding of which an aggregate of up to 562,500 shares were subject to forfeiture to the extent that the underwriters over-allotment option was not exercised in full or in part, so that the initial shareholders would own, on an as-converted basis, 20% of the Companys issued and outstanding shares after the Initial Public Offering (assuming no purchase by the initial shareholders of any Public Shares in the Initial Public Offering). As a result of the underwriters election to fully exercise their over-allotment option, 562,500 Founder Shares are no longer subject to forfeiture.
The Founder Shares will automatically convert into Class A ordinary shares upon consummation of a Business Combination on a one-for-one basis, subject to adjustments as described in Note 6.
The initial shareholders have agreed, subject to limited exceptions, not to transfer, assign or sell any of their Founder Shares until the earlier of (i) one year after the completion of the Companys Business Combination or (ii) the date on which the Company completes a liquidation, merger, share exchange or other similar transaction after the Companys Business Combination that results in all of the Companys shareholders having the right to exchange their Class A ordinary shares for cash, securities or other property. Notwithstanding the foregoing, if the closing price of the Companys Class A ordinary shares equals or exceeds $12.00 per share (as adjusted for share splits, share dividends, reorganizations, recapitalizations and the like) for any 20 trading days within any 30-trading day period commencing at least 150 days after the Companys Business Combination, the Founder Shares will be released from the lock-up.
Private Placement
Simultaneously with the closing of the Initial Public Offering, the Sponsor purchased an aggregate of 5,000,000 Private Placement Warrants at a price of $1.00 per Private Placement Warrant, for an aggregate purchase price of $5,000,000. On August 2, 2019, in connection with the underwriters exercise of the over-allotment option in full, the Company sold an additional 450,000 Private Placement Warrants at a price of $1.00 per Private Placement Warrant, for an aggregate purchase price of $450,000. Each Private Placement Warrant is exercisable to purchase one Class A ordinary share at a price of $11.50 per share. A portion of the proceeds from the Private Placement Warrants were added to the proceeds from the Initial Public Offering held in the Trust Account. If the Company does not complete a Business Combination within the Combination Period, the proceeds of the sale of the Private Placement Warrants will be used to fund the redemption of the Public Shares (subject to the requirements of applicable law), and the Private Placement Warrants and all underlying securities will expire worthless. At the date of the IPO, the fair value of the Private Placement Warrants was $0.62. The difference between the purchase price of $1 and the fair value at the IPO date of $0.62 was recorded within equity as a contribution in excess of the fair value of the Private Placement Warrants.
Administrative Support Agreement
The Company entered into an agreement whereby, commencing on July 16, 2019 and continuing through the earlier of the Companys consummation of a Business Combination and its liquidation, the Company will pay an affiliate of the Sponsor a total of $10,000 per month for office space, secretarial and administrative support. For the three and six months ended June 30, 2021 and 2020, the Company incurred $30,000 and $60,000, respectively, in fees for these services, respectively. As of June 30, 2021 and December 31, 2020, $40,000 and $10,000, respectively, of such fees are included in accounts payable and accrued expenses in the accompanying condensed interim balance sheets.
Advance from Related Party
The Sponsor advanced the Company an aggregate of $32,313 to cover expenses related to the Initial Public Offering. The advances were non-interest bearing and due on demand. In January 2019, the advances were converted into a promissory note issued to the Sponsor (see below).
13
Promissory Note Related Party
In January 2019, the Company issued an unsecured promissory note (the Promissory Note) to the Sponsor, pursuant to which the Company could borrow up to an aggregate principal amount of $300,000. The Promissory Note was non-interest bearing and payable on the earlier of December 31, 2019 or the completion of the Initial Public Offering. In January 2019, the Company transferred its outstanding advance from a related party in the amount of $32,313 into the Promissory Note. The outstanding balance of $254,595 under the Promissory Note was repaid as of December 31, 2019.
On December 30, 2020, the Sponsor deposited $100,000 into the operating bank account of the Company for working capital. An additional $50,000, $35,000 and $850,000 was deposited into the operating bank statement for working capital from the Sponsor on March 22, 2021, March 31, 2021 and April 28, 2021, respectively. On May 25, 2021, the Company issued an unsecured promissory note (the 2021 Promissory Note) in the principal amount of $2,000,000 to the Sponsor. The 2021 Promissory Note does not bear interest and is repayable in full upon consummation of the Companys initial business combination. If the Company does not complete an initial business combination, the 2021 Promissory Note shall not be repaid and all amounts owed under it will be forgiven. The 2021 Promissory Note is subject to customary events of default, the occurrence of which automatically trigger the unpaid principal balance of the 2021 Promissory Note and all other sums payable with regard to the 2021 Promissory Note becoming immediately due and payable. The 2021 Promissory Note was issued pursuant to the exemption from registration contained in Section 4(a)(2) of the Securities Act of 1933, as amended. The advances from the Sponsor on December 30, 2020, March 22, 2021, March 31, 2021 and April 28, 2021, were reclassified as withdrawals as part of the issued promissory note on May 25, 2021. As of June 30, 2021, $1,035,000 is outstanding under the promissory note.
Related Party Loans
In order to finance transaction costs in connection with a Business Combination, the Sponsor or an affiliate of the Sponsor may, but is not obligated to, loan the Company funds as may be required (Working Capital Loans). If the Company completes a Business Combination, the Company would repay the Working Capital Loans out of the proceeds of the Trust Account released to the Company. Otherwise, the Working Capital Loans would be repaid only out of funds held outside the Trust Account. In the event that a Business Combination does not close, the Company may use a portion of proceeds held outside the Trust Account to repay the Working Capital Loans but no proceeds held in the Trust Account would be used to repay the Working Capital Loans. Except for the foregoing, the terms of such Working Capital Loans, if any, have not been determined and no written agreements exist with respect to such loans. The Working Capital Loans would either be repaid upon consummation of a Business Combination or, at the lenders discretion, up to $2,000,000 of such Working Capital Loans may be convertible into warrants of the post Business Combination entity at a price of $1.00 per warrant. The warrants would be identical to the Private Placement Warrants. As of June 30, 2021, and December 31, 2020, no amounts were borrowed under the Working Capital Loans.
Note 5 Commitments and Contingencies
Risks and Uncertainties
Management is continuing to evaluate the impact of the COVID-19 pandemic and has concluded that while it is reasonably possible that the virus could have a negative effect on the Companys financial position, results of its operations and/or search for a target company, the specific impact is not readily determinable as of the date of these condensed financial statements. The condensed interim financial statements do not include any adjustments that might result from the outcome of this uncertainty.
Registration Rights
Pursuant to a registration rights agreement entered into on July 11, 2019, the holders of the Private Placement Warrants, the warrants that may be issued upon conversion of the Working Capital Loans, and the Founder Shares are entitled to registration rights with respect to such warrants and the ordinary shares underlying such warrants and Founder Shares. The holders of these securities are entitled to make up to three demands, excluding short form demands, that the Company register such securities for sale under the Securities Act. In addition, the holders will have certain piggy-back registration rights with respect to registration statements filed subsequent to the completion of a Business Combination. The Company will bear the expenses incurred in connection with the filing of any such registration statements.
14
Underwriting Agreement
The Company granted the underwriters a 45-day option from the date of Initial Public Offering to purchase up to 2,250,000 additional Units to cover over-allotments, if any, at the Initial Public Offering price less the underwriting discounts and commissions. In connection with the underwriters exercise of the over-allotment option in full on August 2, 2019, the underwriters purchased all 2,250,000 additional Units.
The underwriters are entitled to a deferred fee of $6,037,500, which will become payable to them from the amounts held in the Trust Account solely in the event that the Company completes a Business Combination, subject to the terms of the underwriting agreement.
Forward Purchase Agreement
On July 9, 2019, SC Health Group Limited, an affiliate of the Sponsor, entered into a forward purchase agreement with the Company which provides for the purchase by SC Health Group Limited of an aggregate of 5,000,000 Class A ordinary shares, plus an aggregate of 1,250,000 redeemable warrants, each to purchase one Class A ordinary share at $11.50 per share, for an aggregate purchase price of $50,000,000, or $10.00 per Class A ordinary share and accompanying fraction of a warrant in a private placement to close concurrently with the closing of a Business Combination. On July 9, 2019, the Company issued 1,250,000 Founder Shares to the Sponsor in connection with the forward purchase agreement for par value, or $100, of which such shares would be transferred to SC Health Group Limited. The obligations under the forward purchase agreement do not depend on whether any Class A ordinary shares are redeemed by the Companys public shareholders. As part of the Rockley Business Combination, the Company agreed with SC Health Group Limited that the Forward Purchase Agreement should be terminated and instead of purchasing $50,000,000 of Class A ordinary shares pursuant to the forward purchase agreement, SC Health Group Limited would instead enter into the Investor Subscription Agreement referenced below and, pursuant to that agreement, has agreed to purchase an aggregate of $50,000,000 shares in Rockley Photonics Holdings Limited. In connection with the termination of the Forward Purchase Agreement, the company recognized a gain of $2,950,567 with the first quarter of 2021, which is included in the change in FPA liability on the accompanying unaudited condensed interim statements of operations.
Business Combination Agreement
On March 19, 2021, the Company entered into a Business Combination Agreement and Plan of Merger (the Business Combination Agreement), by and among Rockley Photonics Limited, a company incorporated under the laws of England and Wales with company number 08683015 (the Rockley), Rockley Photonics Holdings Limited, an exempted company incorporated in the Cayman Islands with limited liability (HoldCo), and Rockley Mergersub Limited, an exempted company incorporated in the Cayman Islands with limited liability and a direct wholly owned subsidiary of HoldCo (Merger Sub). The Business Combination Agreement and the transactions contemplated thereby (the Rockley Business Combination) were approved by our board of directors and the boards of directors of each of HoldCo, Merger Sub and Rockley.
The Business Combination Agreement provides for, among other things, the following transactions on the closing date: (i) the Company carries out a scheme of arrangement in the UK courts pursuant to which all of the Companys shares (including those issued prior to the scheme as a result of the conversion of convertible loan notes and the exercise of warrants) will be cancelled or transferred by the Companys shareholders in exchange for shares in HoldCo; (ii) the holders of options over shares in the Company will be invited to roll their options into new options over shares in HoldCo; (iii) to the extent convertible loan notes issued by the Company do not convert into shares in the Company prior to the effectiveness of the scheme described in clause (i) above, such notes will, depending on which form the scheme of arrangement takes, either be (a) novated to HoldCo (resulting in HoldCo becoming responsible to issue HoldCo ordinary shares on exercise) and the consideration for the novation shall be an inter-company loan between the Company and HoldCo, or (b) acquired by HoldCo in exchange for the issue of new convertible loan notes by HoldCo to each convertible loan note holder; (iv) the holders of warrants over shares in the Company (other than warrants that by their terms will be replicated at HoldCo in exchange for market value consideration) will be notified that if they do not exercise their warrants for shares in the Company prior to the effectiveness of the scheme described in clause (i) above, then those warrants will lapse; (v) HoldCo will complete a stock-split to prepare its share capital for Merger Subs merger into SC Health; (vi) certain investors will subscribe for and purchase an aggregate of $150,000,000 of shares in HoldCo; (vii) Merger Sub will merge with and into SC Health, with SC Health surviving the merger and becoming a direct wholly-owned subsidiary of HoldCo; and (viii) the shares and warrants in SC Health will be exchanged for shares and warrants in HoldCo.
15
In accordance with the terms and subject to the conditions of the Business Combination Agreement, (i) the existing holders of securities in the Company will exchange their securities for new securities in HoldCo; and (ii) HoldCo will split its stock such that the number of shares in (together with any other securities in or convertible for securities in) HoldCo after the stock split will be equal to $1,148,114,113 divided by $10.00. Certain PIPE investors will subscribe for shares in HoldCo and the warrants in SC Health (each $10.00 shares) will then be exchanged for shares in HoldCo.
Concurrently with the execution of the Business Combination Agreement, the Company and HoldCo entered into subscription agreements (the Investor Subscription Agreements) with certain investors and individuals, including, among others, SC Health Group Limited (an affiliate of the Sponsor), Medtronic, Senvest Management LLC and UBS OConnor. Pursuant to the Investor Subscription Agreements, each investor agreed to subscribe for and purchase, and HoldCo agreed to issue and sell an aggregate of $150,000,000 shares in HoldCo, which will take effect immediately prior to the closing of the Rockley Business Combination.
Previously the Company had entered into a forward purchase agreement with SC Health Group Limited which provided for the purchase by SC Health Group Limited of an aggregate of 5,000,000 Class A ordinary shares, plus an aggregate of 1,250,000 redeemable warrants to purchase one Class A ordinary share at $11.50 per share, for an aggregate purchase price of $50,000,000, or $10.00 per Class A ordinary share and accompanying fraction of a warrant in a private placement to close concurrently with the closing of our initial business combination. As part of the Rockley Business Combination, the Company agreed with SC Health Group Limited that the Forward Purchase Agreement should be terminated and instead of purchasing $50,000,000 of Class A ordinary shares pursuant to the forward purchase agreement, SC Health Group Limited would instead enter into the Investor Subscription Agreement referenced above and, pursuant to that agreement, has agreed to purchase an aggregate of $50,000,000 shares in HoldCo.
Note 6 Shareholders Equity
Preference Shares The Company is authorized to issue to 1,000,000 preference shares with a par value of $0.0001 per share, with such designations, voting and other rights and preferences as may be determined from time to time by the Companys board of directors. At June 30, 2021 and December 31, 2020, there were no preference shares issued or outstanding.
Class A Ordinary Shares The Company is authorized to issue 180,000,000 Class A ordinary shares with a par value of $0.0001 per share. Holders of the Companys Class A ordinary shares are entitled to one vote for each share. At June 30, 2021 and December 31, 2020, there were 4,440,334 and 3,189,208 Class A ordinary shares issued and outstanding, excluding 4,834,181 and 14,060,792 Class A ordinary shares subject to possible redemption, respectively.
Class B Ordinary Shares The Company is authorized to issue to 25,000,000 Class B ordinary shares with a par value of $0.00008 per share. Holders of Class B ordinary shares are entitled to one vote for each share. At June 30, 2021 and December 31, 2020, there were 5,562,500 ordinary shares issued and outstanding.
Holders of Class B ordinary shares will have the right to elect the Companys directors prior to or in connection with the completion of a Business Combination. Holders of Class A ordinary shares and Class B ordinary shares will vote together as a single class on all other matters submitted to a vote of shareholders, except as required by law.
The Class B ordinary shares will automatically convert into Class A ordinary shares at the time of a Business Combination on a one-for-one basis, subject to adjustment as follows. The Class B ordinary shares will automatically convert into Class A ordinary shares on the first business day following the consummation of a Business Combination at a ratio such that the total number of Class A ordinary shares issuable upon conversion of all Founder Shares will equal, in the aggregate, on an as-converted basis, 20% of the total number of Class A ordinary shares outstanding upon completion of this offering, plus the total number of Class A ordinary shares issued or deemed issued or issuable upon conversion or exercise of any equity-linked securities or rights issued or deemed issued, by the Company in connection with or in relation to the consummation of a Business Combination, excluding any Class A ordinary shares or equity-linked securities exercisable for or convertible into Class A ordinary shares issued, or to be issued, to any seller in a Business Combination and any warrants issued in a private placement to the Sponsor or an affiliate of the Sponsor upon conversion of Working Capital Loans.
NOTE 7 Warrant Liabilities
As of June 30, 2021, the Company had 8,625,000 Public Warrants and 5,450,000 Private Placement Warrants outstanding.
Public Warrants may only be exercised for a whole number of shares. No fractional warrants were issued upon separation of the Units, which occurred on September 3, 2019, and only whole warrants will trade. The Public Warrants will become exercisable on the later of (a) 30 days after the completion of a Business Combination or (b) 12 months from the closing of the Initial Public Offering. The Public Warrants will expire five years after the completion of a Business Combination or earlier upon redemption or liquidation.
16
The Company will not be obligated to deliver any Class A ordinary shares pursuant to the exercise of a Public Warrant and will have no obligation to settle such Public Warrant exercise unless a registration statement under the Securities Act with respect to the Class A ordinary shares underlying the Public Warrants is then effective and a prospectus relating thereto is current, subject to the Company satisfying its obligations described below with respect to registration. No warrant will be exercisable and the Company will not be obligated to issue a Class A ordinary share upon exercise of a Public Warrant unless the Class A ordinary share issuable upon such warrant exercise has been registered, qualified or deemed to be exempt under the securities laws of the state of residence of the registered holder of the warrants.
The Company has agreed that as soon as practicable, but in no event later than thirty (30) business days after the closing of a Business Combination, it will use its best efforts to file with the SEC a registration statement for the registration, under the Securities Act, of the Class A ordinary shares issuable upon exercise of the Public Warrants. The Company will use its best efforts to cause the same to become effective and to maintain the effectiveness of such registration statement, and a current prospectus relating thereto, until the expiration of the warrants in accordance with the provisions of the warrant agreement. If a registration statement covering the Class A ordinary shares issuable upon exercise of the warrants is not effective by the sixtieth (60th) day after the closing of a Business Combination, warrant holders may, until such time as there is an effective registration statement and during any period when the Company will have failed to maintain an effective registration statement, exercise warrants on a cashless basis in accordance with Section 3(a)(9) of the Securities Act or another exemption.
Redemption of Warrants for Cash. Once the warrants become exercisable, the Company may redeem the Public Warrants:
|
in whole and not in part; |
|
at a price of $0.01 per warrant; |
|
upon not less than 30 days prior written notice of redemption; and |
|
if, and only if, the reported last sales price of the Companys Class A ordinary shares equals or exceeds $18.00 per share for any 20 trading days within a 30-trading day period ending on the third trading day prior to the date on which the Company sends the notice of redemption to the warrant holders. |
If and when the warrants become redeemable by the Company, the Company may exercise its redemption right even if it is unable to register or qualify the underlying securities for sale under all applicable state securities laws.
Redemption of Warrants for Class A Ordinary Shares. Commencing ninety days after the warrants become exercisable, the Company may redeem the outstanding Public Warrants:
|
in whole and not in part; |
|
at a price equal to a number of Class A ordinary shares to be determined, based on the redemption date and the fair market value of the Companys Class A ordinary shares; |
|
upon a minimum of 30 days prior written notice of redemption; |
|
if, and only if, the last reported sale price of the Companys Class A ordinary shares equals or exceeds $10.00 per share (as adjusted for share splits, share dividends, reorganizations, recapitalizations and the like) on the trading day prior to the date on which the Company sends the notice of redemption to the warrant holders; |
|
if, and only if, the Private Placement Warrants are also concurrently exchanged at the same price (equal to a number of Class A ordinary shares) as the outstanding Public Warrants; and |
|
if, and only if, there is an effective registration statement covering the Class A ordinary shares issuable upon exercise of the warrants and a current prospectus relating thereto available throughout the 30-day period after written notice of redemption is given |
If the Company calls the Public Warrants for redemption, management will have the option to require any holder that wishes to exercise the Public Warrants to do so on a cashless basis, as described in the warrant agreement. The exercise price and number of ordinary shares issuable upon exercise of the warrants may be adjusted in certain circumstances including in the event of a share dividend, or recapitalization, reorganization, merger or consolidation. However, the warrants will not be adjusted for issuance of ordinary shares at a price below its exercise price. Additionally, in no event will the Company be required to net cash settle the warrants. If the Company is unable to complete a Business Combination within the Combination Period and the Company liquidates the funds held in the Trust Account, holders of warrants will not receive any of such funds with respect to their warrants, nor will they receive any distribution from the Companys assets held outside of the Trust Account with the respect to such warrants. Accordingly, the warrants may expire worthless.
17
In addition, if (x) the Company issues additional Class A ordinary shares or equity-linked securities for capital raising purposes in connection with the closing of a Business Combination at an issue price or effective issue price of less than $9.20 per ordinary share (with such issue price or effective issue price to be determined in good faith by the Company) and, (i) in the case of any such issuance to the Sponsor or its affiliates, without taking into account any Founder Shares held by the Sponsor or such affiliates, as applicable, prior to such issuance, and (ii) to the extent that such issuance is made to SIN Capital Group Pte. Ltd., an affiliate of the Company and the Sponsor or its affiliates, without taking into account the transfer of Founder Shares or Private Placement Warrants (including if such transfer is effectuated as a surrender to the Company and subsequent reissuance by the Company) by the Sponsor in connection with such issuance) (the Newly Issued Price), (y) the aggregate gross proceeds from such issuances represent more than 60% of the total equity proceeds, and interest thereon, available for the funding of a Business Combination on the date of the consummation of a Business Combination (net of redemptions), and (z) the volume weighted average trading price of our Class A ordinary shares during the 20 trading day period starting on the trading day prior to the day on which the Company consummates a Business Combination (such price, the Market Value) is below $9.20 per share, the exercise price of the warrants will be adjusted (to the nearest cent) to be equal to 115% of the higher of the Market Value and the Newly Issued Price, and the $18.00 per share redemption trigger price will be adjusted (to the nearest cent) to be equal to 180% of the higher of the Market Value and the Newly Issued Price.
The Private Placement Warrants are identical to the Public Warrants underlying the Units sold in the Initial Public Offering, except that the Private Placement Warrants and the Class A ordinary shares issuable upon the exercise of the Private Placement Warrants will not be transferable, assignable or salable until 30 days after the completion of a Business Combination, subject to certain limited exceptions. Additionally, the Private Placement Warrants will be exercisable on a cashless basis and be non-redeemable (for cash) so long as they are held by the initial purchasers or their permitted transferees. If the Private Placement Warrants are held by someone other than the initial purchasers or their permitted transferees, the Private Placement Warrants will be redeemable by the Company and exercisable by such holders on the same basis as the Public Warrants.
Note 8 Fair Value Measurements
The fair value of the Companys financial assets and liabilities reflects managements estimate of amounts that the Company would have received in connection with the sale of the assets or paid in connection with the transfer of the liabilities in an orderly transaction between market participants at the measurement date. In connection with measuring the fair value of its assets and liabilities, the Company seeks to maximize the use of observable inputs (market data obtained from independent sources) and to minimize the use of unobservable inputs (internal assumptions about how market participants would price assets and liabilities). The following fair value hierarchy is used to classify assets and liabilities based on the observable inputs and unobservable inputs used in order to value the assets and liabilities:
Level 1: | Quoted prices in active markets for identical assets or liabilities. An active market for an asset or liability is a market in which transactions for the asset or liability occur with sufficient frequency and volume to provide pricing information on an ongoing basis. | |
Level 2: | Observable inputs other than Level 1 inputs. Examples of Level 2 inputs include quoted prices in active markets for similar assets or liabilities and quoted prices for identical assets or liabilities in markets that are not active. | |
Level 3: | Unobservable inputs based on our assessment of the assumptions that market participants would use in pricing the asset or liability. |
The Company classifies its U.S. Treasury and equivalent securities within the Trust Account as held-to-maturity in accordance with ASC Topic 320 InvestmentsDebt and Equity Securities. Held-to-maturity securities are those securities which the Company has the ability and intent to hold until maturity. Held-to-maturity treasury securities are recorded at amortized cost on the accompanying condensed balance sheets and adjusted for the amortization or accretion of premiums or discounts.
At June 30, 2021, assets held in the Trust Account were comprised of $93,838,960 in money market funds, which are invested in U.S. Treasury Securities. At December 31, 2020, assets held in the Trust Account were comprised of $174,542,012 in money market funds, which are invested in U.S. Treasury Securities, For the money market funds that the Trust Accounts are invested in, the fair market value of the money market funds is equivalent to the amortized cost value. During the three and six months ended June 30, 2021 or 2020, the Company did not withdraw any interest income from the Trust Account.
18
At June 30, 2021 and December 31, 2020, there were 5,450,000 Public Warrants and 8,625,000 Private Placement Warrants outstanding. Additionally, there were 0 and 5,000,000 Class A ordinary shares with an accompanying fractional warrant outstanding in relation to the Forward Purchase Agreement as of June 30, 2021, and December 31, 2020 outstanding, respectively.
The following table presents information about the Companys assets and liabilities that are measured at fair value on a recurring basis at June 30, 2021 and December 31, 2020 and indicates the fair value hierarchy of the valuation inputs the Company utilized to determine such fair value.
Description | Level |
June 30,
2021 |
December 31,
2020 |
|||||||||
Assets: |
||||||||||||
Marketable securities held in Trust Account U.S. Treasury Securities Money Market Fund |
1 | $ | 93,838,960 | $ | 174,542,012 | |||||||
Liabilities: |
||||||||||||
Private Placement Warrants |
3 | $ | 14,304,182 | $ | 7,412,000 | |||||||
Public Warrants |
1 | 18,198,750 | 11,643,750 | |||||||||
Forward Purchase Agreement (FPA) |
3 | | 2,950,567 |
The Warrants and FPA were accounted for as liabilities in accordance with ASC 815-40 and are presented within warrant liabilities on the condensed balance sheets. The warrant liabilities are measured at fair value at inception and on a recurring basis, with changes in fair value presented within change in fair value of warrant liabilities and FPA in the condensed statements of operations.
The Company established the initial fair value for the private and public warrants and the FPA on July 16, 2019, the date of the Companys Initial Public Offering, using various valuation methodologies. The Private Placement Warrants were initially measured using a Modified Black-Scholes, the public warrants were initially measured using a Monte Carlo simulation, and the FPA was initially measured using a forward valuation model. The initial measurement of the liabilities was classified as Level 3 due to the use of unobservable inputs.
The subsequent measurement of the private warrants is performed using Modified Black-Scholes Model. The public warrants are subsequently measured at the trading stock price at the end of the reporting periods. The FPA is no longer measured due to the termination described in Note 5.
The key inputs into the Modified Black-Scholes Model for the Private Placement Warrants were as follows at June 30, 2021 and December 31, 2020:
Input |
June 30,
2021 |
December 31,
2020 |
||||||
Risk-free interest rate |
0.91 | % | 0.40 | % | ||||
Time to Maturity (Years) |
5.25 | 5.29 | ||||||
Implied volatility |
40.0 | % | 19.00 | % | ||||
Exercise price |
$ | 11.50 | $ | 11.50 | ||||
Implied Stock Price |
$ | 10.08 | $ | 10.25 |
The following table presents the changes in the fair value of level 3 warrant and FPA liabilities:
19
Forward
Purchase Agreement |
Private
Placement Warrants |
|||||||
Fair value as of December 31, 2020 |
$ | 2,950,567 | $ | 7,412,000 | ||||
Change in fair value |
| 9,588,092 | ||||||
Termination of FPA |
(2,950,567 | ) | | |||||
|
|
|
|
|||||
Fair value as of March 31, 2021 |
| $ | 17,000,092 | |||||
Change in fair value |
| (2,695,910 | ) | |||||
|
|
|
|
|||||
Fair value as of June 30, 2021 |
$ | | $ | 14,304,182 | ||||
|
|
|
|
There were no transfers in or out of Level 3 from other levels in the fair value hierarchy during the three and six months ended June 30, 2021.
Note 9 Subsequent Events
The Company evaluated subsequent events and transactions that occurred after the condensed balance sheet date up to the date that the unaudited condensed interim financial statements were issued. Based upon this review, the Company did not identify any subsequent events that would have required adjustment or disclosure in the unaudited condensed interim financial statements.
20
Exhibit 99.1
Rockley Photonics Announces Successful Closing of Business Combination with SC Health Corp.
Rockley receives approximately $168 million in gross proceeds; combined company to begin trading under ticker RKLY on August 12
Oxford, UK, and Pasadena, Calif. August 11, 2021 Rockley Photonics, Ltd. (the Company or Rockley), a leading global silicon photonics technology company, today announced the completion of its business combination with SC Health Corp. (SC Health). The combined company will retain the Rockley Photonics, Ltd. name as a subsidiary of Rockley Photonics Holdings, Ltd., which will commence trading on the NYSE under the new ticker symbol RKLY on August 12. The transaction was approved by SC Healths shareholders on August 6, following which the High Court of Justice of England and Wales approved the Scheme of Arrangement on August 9.
The approximately $167.8 million in gross proceeds available to Rockley following the combination is expected to enable the Company to accelerate the commercial launch of its unique sensing platform and execute the 2023 and 2024 revenue projections as outlined in prior investor presentations. The platform is positioned to revolutionize consumer health and wellness by enabling continuous, non-invasive monitoring of multiple biomarkers, including core body temperature, blood pressure, body hydration, alcohol, lactate, and glucose, among others. Rockley is working closely and deeply with some of the worlds largest manufacturers of consumer electronics and wearables to provide them with a clinic-on-the-wrist digital health sensor system. Rockleys end-to-end sensing platform will combine hardware and application firmware in a module for OEM manufacturers that can be augmented with cloud analytics for certain clinical/medical partnership applications, enabling these customers to provide meaningful and actionable insights to their users.
Silicon photonics has tremendous potential to transform multiple industries through a broad range of applications, particularly in the health and wellness space by bringing laboratory-grade measurement on the wrist much closer to reality, said Dr. Andrew Rickman, chief executive officer and founder of Rockley Photonics. As we continue on the next phase of our growth as a public company, we are in a much stronger position to create solutions that can provide a new class of actionable insights, transform digital healthcare, and deliver life-changing benefits to people across the globe.
A.J. Coloma, chief executive officer of SC Health, added, Rockleys technology is truly revolutionary. By giving access to personalized insights and information, Rockleys unique sensing platform lets people self-manage their well-being. Easy, everyday access to this data has the power to transform the healthcare paradigm, moving away from costly chronic care and focusing on prevention and early intervention, thereby keeping people at the peak of health. Rockley is now well poised to further solidify their leadership position in the industry, and we are excited about the abundance of growth opportunities ahead, not only in the consumer health space, but also in medtech and beyond. We look forward to continuing to work alongside Andrew and his team to fully realize the myriad applications of the companys technology.
Board of Directors
With the completion of this business combination, Rockley also announced the appointment of a diverse board of directors. The new board will comprise of seven directors, including three women and one self-identified minority director, who bring extensive public company board experience and deep expertise in each of their respective fields:
|
Dr. Andrew Rickman, Ph.D., OBE1, Rockley CEO and founder, will serve as chairman of the board. |
1 |
Order of the British Empire |
Page 1 of 4
|
William Huyett is director emeritus of McKinsey and Company, where he spent 30 years serving global clients in biopharmaceuticals, medical devices, industrial, and other technology-intensive companies. Mr. Huyett will serve as senior independent director. |
|
Dr. Caroline Brown, Ph.D., has 20 years of board experience, has been an independent director on Rockleys board since January 2019, and sits on the boards of IP Group plc, Georgia Capital plc and Luceco plc. Dr. Brown has been appointed as chair of audit committee. |
|
Brian J. Blaser has over 25 years of experience in the medical devices industry and retired from Abbott Laboratories in 2019 as executive vice president of diagnostic products after holding a number of senior and corporate roles in operations and strategy. |
|
Karim Karti, a healthcare industry veteran, is the chair of MedTech Acquisition, was previously the chief operating officer of iRhythm Technologies, and served in roles of increasing seniority over 22 years at General Electric. |
|
Michele Klein has 20 years of semiconductor industry experience and serves on the boards of Aviat Networks and Intevac. Earlier she was a director of Photon Control, an investor for Applied Ventures, the VC arm of Applied Materials, and CEO of diagnostic equipment companies. |
|
Dr. Pamela Puryear, Ph.D., an expert on human capital, is the executive vice president of global human resources at Walgreen Boots and was previously a senior vice president and chief human resources at Zimmer Biomet and the senior vice president and chief talent officer at Pfizer. |
Transaction Details
As a result of the business combination, Rockley has received approximately $167.8 million in gross proceeds. This includes $17.8 million from SC Health, as well as $150 million from the financing completed in connection with the announcement of the business combination, led by top-tier institutional investors including Senvest Management LLC and UBS OConnor and participation from Medtronic.
Advisors
Cowen and Company LLC served as exclusive financial advisor to Rockley and Pillsbury Winthrop Shaw Pittman LLP served as legal counsel. BofA Securities served as exclusive financial advisor to SC Health and Ropes & Gray LLP served as legal counsel. BofA Securities and Cowen and Company LLC served as placement agents on the PIPE.
About Rockley Photonics
A global leader in silicon photonics, Rockley is developing a comprehensive range of photonic integrated circuits and associated modules, sensors, and full-stack solutions. From next-generation sensing platforms specifically designed for mobile health monitoring and machine vision to high-speed, high-volume solutions for data communications, Rockley is laying the foundation for a new generation of applications across multiple industries. Rockley believes that photonics will eventually become as pervasive as micro-electronics, and it has developed a platform with the power and flexibility needed to address both mass markets and a wide variety of vertical applications.
Formed in 2013 by Dr. Andrew Rickman (who previously founded the first commercial silicon photonics company, Bookham Technology), Rockley is uniquely positioned to support hyper-scale manufacturing and address a multitude of high-volume markets. Rockley has partnered with numerous Tier-1 customers across a diverse range of industries to deliver the complex optical systems required to bring transformational products to market.
Page 2 of 4
To learn more about Rockley, visit rockleyphotonics.com.
Cautionary Statement Regarding Forward-Looking Statements
Certain statements in this press release that are not historical facts constitute forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include statements regarding Rockleys future expectations, beliefs, plans, objectives, and assumptions regarding future events or performance. The words anticipate, believe, continue, could, enable, estimate, eventual, expect, future, intend, may, might, opportunity, outlook, plan, possible, position, potential, predict, project, revolutionize, seem, should, trend, will, would and other terms that predict or indicate future events, trends, or expectations, and similar expressions or the negative of such expressions may identify forward-looking statements, but the absence of these words or terms does not mean that a statement is not forward-looking. Forward-looking statements in this press release include, but are not limited to, statements regarding the following: (a) the gross proceeds available to the Company after the business combination, the Companys anticipated use of proceeds and capital available after the business combination, and that such proceeds are expected to enable the Company to accelerate the commercial launch of its sensing platform; (b) the anticipated features and benefits of the Companys platform, products, and technology; (c) the Companys platform being positioned to revolutionize consumer health and wellness by enabling continuous, non-invasive monitoring of multiple biomarkers, including core body temperature, blood pressure, body hydration, alcohol, lactate, and glucose, among others; (d) the Companys collaboration with manufacturers of consumer electronics and wearables to provide them with a clinic-on-the-wrist digital health sensor system; (e) the Companys sensing platform, which will combine hardware and application firmware in a module that can be augmented with cloud analytics, and the anticipated benefits thereof; (f) the ability of the capital from the business combination to advance the development of commercial opportunities for the application of silicon photonics across industries; (g) the potential of silicon photonics to transform multiple industries through a range of applications; (h) the Companys ability to create solutions that can provide a new class of actionable insights, transform digital healthcare, and deliver life-changing benefits; (i) the belief as to the revolutionary nature of Rockleys technology; and (j) growth opportunities and Rockleys leadership position in the industry.
Forward-looking statements are subject to several risks and uncertainties (many of which are beyond the Companys control) or other assumptions that may cause actual results or performance to differ materially from those expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to, the following: (i) the Companys ability to achieve commercial production of its products and technology, including in a timely and cost-effective manner; (ii) the Companys ability to achieve customer design wins, convert memoranda of understanding and development contracts into production contracts, and achieve customer acceptance of its products and technology; (iii) risks related to purchase orders, including the lack of long-term purchase commitments, the cancellation, reduction, delay, or other changes in customer purchase orders, and if and to the extent customers seek to enter into licensing arrangements in lieu of purchases; (iv) the Companys history of losses and need for additional capital and its ability to access additional financing to support its operations and execute on its business plan, as well as the risks associated with any future financings; (v) legal and regulatory risks, including those related to its products and technology and any threatened or actual litigation; (vi) risks associated with its fabless manufacturing model and dependency on third-party suppliers; (vii) the Companys reliance on a few significant customers for a majority of its revenue and its ability to expand and diversify its customer base; (viii) the Companys financial performance; (ix) the impacts of COVID-19 on the Company, its customers and suppliers, its target markets, and the economy; (x) the Companys ability to successfully manage growth and its operations as a public company; (xi) fluctuations in the Companys stock price and the Companys ability to maintain the listing of its ordinary shares on the NYSE; (xii) the Companys ability to anticipate and respond to industry trends and customer requirements; (xiii) changes in the Companys current and future target markets; (xiv) intellectual property risks; (xv) the Companys ability to compete successfully; (xvi) market opportunity and market demand
Page 3 of 4
for, and acceptance of, the Companys products and technology, as well as the customer products into which the Companys products and technology are incorporated; (xvii) risks related to international operations; (xviii) risks related to cybersecurity, privacy, and infrastructure; (xix) risks related to financial and accounting matters; (xx) general economic, financial, legal, political, and business conditions and changes in domestic and foreign markets; (xxi) the Companys ability to realize the anticipated benefits of the business combination; and (xxii) changes adversely affecting the businesses or markets in which the Company is engaged, as well as other factors described under the heading Risk Factors in the prospectus/proxy statement filed by the Company on July 22, 2021 and in other documents the Company files with the Securities and Exchange Commission in the future. The forward-looking statements contained in this press release are based on various assumptions, whether or not identified in this press release, and on the Companys current expectations, beliefs, and assumptions and are not predictions of actual performance. If any of these risks or uncertainties materialize, or should any of these assumptions prove incorrect, actual results may differ materially from those discussed in or implied by these forward-looking statements. There can be no assurance that future developments affecting the Company will be those that have been anticipated. These forward-looking statements speak only as of the date hereof and the Company specifically disclaims any obligation to update or revise any forward-looking statements, whether because of new information, future events, or otherwise.
Contact Information
For Rockley
Media
John Christiansen, Camilla Scassellati Sforzolini
Sard Verbinnen & Co
Rockley-SVC@sardverb.com
Investors
Gwyn Lauber
Vice President of Investor Relations
Rockley Photonics
investors@rockleyphotonics.com
# # #
Page 4 of 4